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With the advent of the direct-to-consumer advertising strategy, promoting pharmaceutical drugs 
directly to consumers, rather than to physicians, became mainstream. The use of this strategy has 
produced widespread effects on a variety of actors and institutions including patients, physicians, 
and health care providers. This thesis conducts a case study of the persuasive elements, cues, and 
strategies of direct-to-consumer advertisements for pharmaceuticals treating for cardiac 
conditions. The analysis examines the print advertising campaigns of five market-leading 
pharmaceuticals in their category in mainstream media channels. To make these messages 
persuasive and elicit compliance and awareness from consumers, advertisers have relied on a 
variety of strategies including scare tactics, humor, emotional appeals, and rationality appeals. 
From the analysis, it was concluded that the advertisements do not provide enough information 
to consumers, portray only positive outcomes of the targeted medical condition, seek to empower 
the consumer, and contribute to the medicalization trend experienced in American society today.
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I. Introduction  
This research is concerned with prescription drug advertising and the introduction of the 
direct-to-consumer (DTC) advertising strategy into the marketing mix of pharmaceutical drugs. 
The changes wrought by this new approach on consumers, health care providers, and physicians 
have been widespread and have sparked scholarly debate, concern, and interest. This paper will 
examine this phenomenon and the particular conditions that caused and enabled the shift in 
health advertising strategies from targeting physicians to addressing patients directly. Most 
significantly, this research will analyze the elements used in mass media messages produced to 
sell prescription drugs in today’s pharmaceutical market.  
Over the last thirty years, as a result of social, economic, and regulatory changes, drug 
advertising has undergone a fundamental transformation. Today, the consumer—the patient—is 
addressed directly while the physician—the agent—is bypassed by advertising agencies. Instead 
of working hard to promote their products to physicians who have the power to prescribe 
medications to patients who require them, drug companies are circumventing doctors’ authority 
and addressing potential patients directly. In turn, “patients”, who are potentially totally healthy 
individuals, can actively seek sometimes-unnecessary medications they have seen in an 
advertisement from their physicians. The result of this change is a profound impact on the drug 
market, the enforcement of drug control, prescription behavior on the part of physicians and a 
drastic change in patient-physician relationships. This is a significant social trend that warrants 
further examination and must be better understood in order to determine its potentially dangerous 
and problematic long-term effects. 
Much literature exists on the topic of drug advertising and the changes it has undergone in 
the last several decades. Some studies have already been conducted in an effort to describe these 
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trends. Both quantitative and qualitative analyses of direct-to-consumer messages and the 
pharmaceutical drug market have been performed by scholars and interested parties and have 
established that new advertisements and brand introductions have increased dramatically in the 
last thirty years. Previous studies have also gathered information on the target audiences, 
common appeals, and marketing techniques prevalent and discernible in health advertisements. 
This issue has a wide scope of influence and has accordingly been examined by academics from 
the points of view of physicians, patients, and advertisers in turn to decipher the effects of direct-
to-consumer advertising on different individuals and institutions.  
 This paper aims to review the events and changes that led to the shift in reliance of 
advertisers from physicians to consumers in marketing pharmaceuticals. Prefaced by the 
historical overview of regulatory, social, and economic conditions leading up to the change in 
pharmaceutical advertising tactics, this paper will examine these new techniques through a study 
of print ad campaigns. This study aims to identify overarching themes and analyze unique 
elements in the print ad campaigns of several prominent drug brands used to treat cardiovascular 
conditions. From this analysis, this thesis hopes to address the following questions: How do 
advertisers make drugs an attractive commodity to patients? What kinds of tactics are used to 
achieve compliance (i.e. sales)? How do advertising agencies create successful marketing 
campaigns promoting drugs to consumers who may not need them?  
This study is significant because the direct-to-consumer marketing strategy has wide-cast 
implications on a variety of people and institutions: physicians, patients, government, and health 
care providers. The availability, accessibility, and new legitimacy of prescription drugs may have 
started as an effort to educate the public and eliminate potential physicians’ ethical dilemmas, 
but has resulted in a changed social order and a climate conducive to potentially risky and unsafe 
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prescription drug use by patients who may not necessitate pharmacological treatment. It is 
important to examine how this trend has unfolded to attempt to identify some future possible 
effects of these changes. This examination, in turn, may provide an important basis for continued 
studies of the direct-to-consumer strategy and may prove useful in an effort to create policy to 
regulate advertising and to ensure safe pharmaceutical drug use and the availability of adequate 
information to the lay public. In addition, while most recent studies have focused on television 
advertisements for pharmaceuticals, as television has become the medium of choice for the 
majority of Americans today and advertising in this medium has accordingly increased 
dramatically in the last decades, this thesis proposes to contribute to the existing body of 
literature by concentrating on less-studied, though still significant, print advertisements.  
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II. Literature Review 
 Direct-to-consumer advertising is defined as “any promotional effort by a pharmaceutical 
company to present prescription drug information to the general public through the lay media, 
including newspapers, periodicals, television and radio.” (Cline, 2004, p. 134). In the last 25 
years, the volume of prescription drug advertising efforts aimed directly at consumers, rather 
than physicians, has increased exponentially. Between 1996 and 2003, there was a 400% recoded 
increase in pharmaceutical companies’ spending on direct-to-consumer advertising (Gellad, 
2007, p. 475). Spending on this type of advertising has risen from $47 million in 1990 to over 
$3.2 billion in 2003 (Kaphingst, 2004, p. 517). This steep intensification in concentrated 
spending has raised concerns among the public, the medical community, the government, and 
health care providers. Worry about direct-to-consumer advertising’s impact on pharmaceutical 
prices and expenditures, consumer information, physicians’ prescribing behavior, and the 
patient-physician relationship has led to increased interest, scholarship, and monitoring of this 
strategy and the trends it has set in motion (Calfee, 2002).  
 
A. Environmental conditions: how it all started 
 What factors led to the increase in spending on direct-to-consumer advertising of 
prescription drugs? This section will identify the turning point in drug marketing tactics when 
direct-to-consumer advertisements began to proliferate in popular media venues and trace the 
conditions that enabled this change to occur.  
 
1. Social conditions 
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The pharmaceutical industry first proposed changing its marketing approach to include 
directly addressing consumers in 1981. Appealing to the Food and Drug Administration, the 
federal agency responsible for protecting and promoting public health through the regulation and 
supervision of goods such as pharmaceutical drugs, pharmaceutical companies justified their 
proposed changes by citing the public benefit from this type of advertising (Wilkes, 2000, p. 
114). The pharmaceutical industry argued that direct-to-consumer advertising could do more 
than the current model of simply providing the public with access to important drug information: 
by addressing the public directly, the drug industry and government agencies could protect the 
consumer more fully. The industry claimed that the educational benefits of advertising directly to 
the consumer were immense (Wilkes, 2000, p. 115). 
Direct-to-consumer advertising, pharmaceutical companies and proponents of the 
strategy argued, could increase treatment of under-diagnosed conditions, inform consumers 
about new available treatments, and help consumers make better-informed decisions pertaining 
to their health and well-being (Kaphingst, 2004, p. 144). These advertisements would also give 
consumers the information necessary to discuss symptoms and treatment options with their 
physicians (Becker, 2005, p. 441). By giving patients sufficient information and empowering 
them to discuss medical conditions they may not have previously thought of with a physician, 
this strategy was argued to offer significant benefits. Lastly, proponents argued that this form of 
advertising, by the nature of its persistence and availability in mainstream communication 
channels, could increase patients’ compliance with treatments because of the constant reminders 
aimed at them on a regular basis.  
Some support for the direct-to-consumer advertising strategy was based on previous 
studies that found that it was possible to influence individuals to exercise personal responsibility 
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for their health using mass media channels. These communication channels could be used to 
disseminate information and educate the public about possible dangers and risks (McGuire, 
1984, p. 303). These messages were found to motivate individuals to reduce health hazards by 
adopting a more healthful lifestyle. On the basis of this premise, proponents of direct-to-
consumer advertising argued that pharmaceutical companies could achieve similar results by 
motivating individuals to seek treatment for conditions by mentioning the advertised drugs to 
their physicians. 
Another presumed advantage of direct-to-consumer advertising was that it could 
significantly reduce (or virtually eliminate) pharmaceutical companies’ previous system of 
marketing drugs to doctors. The practice of offering expensive gifts, including entertainment, 
recreation, travel, and expensive meals, or illegal kickbacks, such as cash payments or other 
benefits, to influence physicians had brought the ethics of physician prescription practices under 
close scrutiny (Consumer Reports, 1996, p. 62). If the promotion offer was effective, physicians 
would prescribe the promoted brand of drug to patients and in that way directly increase the 
brand’s sales and market share (Becker, 2005, p. 442).  This issue was one of substantial 
discomfort and worry for the American public and government agencies, and the prospect of 
introducing the consumer into the drug decision equation and mediating the physician’s control 
of the drug market was very appealing to some of those concerned. Providing consumers with 
information directly, pharmaceutical companies argued, would give the consumer power to seek 
out appropriate medications and not rely entirely on their physicians to make prescription 
decisions. In turn, this change would reduce the pharmaceutical companies’ need to “court” 
physicians to disseminate and promote their products (Consumer Reports, 1996, p. 62).  
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On the other end of the spectrum, these proposed changes in advertising strategy also 
raised significant concerns. Opponents of the direct-to-consumer advertising proposition argued 
that this strategy is inappropriate because such messages could confuse individuals who lack 
specialized medical knowledge (Kaphingst, 2004, p. 515). These same individuals are not in a 
position to independently diagnose conditions or evaluate the safety, effectiveness or 
appropriateness of different possible treatments (Becker, 2005, p. 446). The impact on the 
patient-physician relationship was also perceived to be at risk by this change. Health care 
professionals worried that direct-to-consumer advertising could undermine this important 
relationship if patients began to use their new knowledge to pressure physicians to prescribe 
drugs which they had seen in an advertisement. This, in turn, could lead to inappropriate 
prescribing behavior on the part of physicians as well as prescription drug misuse and abuse by 
patients (Findlay, 2001, p. 109). Lastly, some also worried that advertising branded drugs would 
unnecessarily increase demand and consumption of new, expensive medications over older, 
cheaper, and safer alternatives (Hollon, 1999, p. 382). As a result of this, health care costs would 
increase and the financial burden on insurance companies and health care providers would 
heighten (Kaphingst, 2004, p. 144). 
2. Regulatory conditions  
The appeals from pharmaceutical companies conveniently coincided with the political 
and regulatory climate of the time, which was swinging toward giving consumers more choice 
and legitimacy to take part in the medical decision-making process (Wilkes, 2000, p. 120). 
According to a longitudinal study conducted by Consumer Reports (1996, p. 62), the overall 
trend has been one of deregulation, with increasing power and privileges being handed to 
pharmaceutical companies. Nevertheless, in response to this push for a new type of advertising 
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targets, the U.S. Food and Drug Administration (FDA) laid out a series of regulations for 
prescription drug advertisements aimed directly at consumers. This regulation was designed to 
be particularly stringent. Because FDA staff do not always review ads before they are published, 
it was necessary to establish a provision that would enforce compliance with regulation standards 
(Calfee, 2002).  
The FDA divides direct-to-consumer advertising into three categories, but regulates only 
“product-claim advertisements”, which contain specific efficacy and safety information of a 
particular drug (Gellad, 2007, p. 476). Most basically, these guidelines mandate that prescription 
drug advertisements be clear and accurate and not false or misleading. The ads are required to 
present a “fair balance” of the drug’s risks and benefits (Kaphingst, 2004, p. 143). In addition, 
this risk information must be prominent and readable in the main body copy (Roth, 1996, p. 66).  
Direct-to-consumer advertisements in print form must specifically include a “brief summary” 
describing the drug’s uses, side effects, warnings, precautions, contraindications, and 
effectiveness (Kaphingst, 2004, p. 300).  
Regulations for broadcast direct-to-consumer advertisements vary slightly from print 
advertisements. Primarily, television and radio advertisements must include a “major statement” 
of the significant risks and most commonly-occurring adverse side effects of the drug in either 
the audio or visual parts of the presentation (Gellad, 2007, p. 478). In addition, the FDA requires 
either a “brief summary” that gives detailed information about said adverse effects or “adequate 
provision” for these side-effects in a different channel (Kaphingst, 2004, p. 515). The FDA 
further gave power to pharmaceutical companies by clarifying that the “adequate provision” 
requirement could also be fulfilled by referring consumers to physicians for additional 
information. Alternatively, consumers could be directed to a brand’s website, toll-free telephone 
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number, or a concurrent print advertisement for more information (Talley, 1997, p. 2181). 
Broadcast advertisers were also required to use “consumer-friendly language” in describing 
major risks in the advertisements (Kaphingst, 2004, p. 515).  
 FDA approval of advertisements before they are published or disseminated is not 
required. While ads must only be submitted as they go to air, however, most companies 
voluntarily submit drafts of advertisements to the agency to reduce the possibility of later official 
recall by the FDA (Kaphingst, 2004, p. 516). If the FDA does identify an ad that violates 
regulations, the drug company receives a citation. Nevertheless, only a small percentage of 
advertisements have been subjected to this measure, and the FDA has yet to enact more severe 
consequences like obtaining court injunctions to seize products promoted through false or 
misleading means (Kaphings, 2004, p. 520).  
 From this review of regulation, it is clear that efforts were made to control and 
standardize advertisements of prescription drugs to ensure consumer safety and exposure to 
adequate necessary information prior to beginning a course of pharmaceutical treatment. 
Nevertheless, it remains unclear whether the advertisements contain and communicate 
information in a manner that is best suited for consumers.  
3. Economic conditions 
Although there has not been much evidence gathered in literature on this issue, it is 
essential to mention the economic incentives and market conditions that gave rise to the direct-
to-consumer advertising strategy. Many skeptics argue that although the pharmaceutical industry 
cites providing educational information to consumers to be the major reason behind switching to 
direct-to-consumer advertising tactics, the “bottom-line desire for profit is undoubtedly another.” 
(Hollon, 1999, p. 382). As technology and scientific discovery grow and innovate, it becomes 
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increasingly difficult to produce a revolutionary, one-of-a-kind drug that will dominate the 
market. Competing in an expanding market full of brand-name alternatives and struggling to 
make a profit, the direct-to-consumer approach opens new possibilities before marketers and an 
untapped source of potential consumers to address and persuade.  
In addition to competition from other brand-name drugs, pharmaceutical drug companies’ 
products are rivaled by generics that flood the pharmaceutical market as soon as a brand’s patent 
expires. While patents last for 20 years before they expire, they are rarely granted immediately 
for pharmaceutical products (Federal Drug Administration, 2010). Instead, the FDA grants 
exclusivity rights—which like patents grant companies the exclusive rights to a product—for 
only seven years for an “orphan drug” (Federal Drug Administration, 2010). This exclusivity 
provision was designed precisely to promote some balance between brand-name drugs and their 
generic competition. Nevertheless, once this exclusivity expires it is up to the pharmaceutical 
company to convince consumers that their brand-name product is superior to its cheaper generic 
counterpart. Faced with the threat of dropping sales, pharmaceutical companies face pressure to 
maintain or increase the market success of their products. Turning to marketing to achieve these 
ends, "The winners in the prescription drug category are not…the ones with the best patents or 
products, but those that are the best marketers." (Freeman, 1998, p. S7).  
In addition to economic conditions in a competitive marketplace and the need to expand 
market share and reap profits, the economic environment also stood to change from this shift in 
advertising targets. Since consumers must obtain a physician’s prescription before purchasing a 
drug, the necessity of visiting a physician was projected to increase in accordance with the 
increased exposure of consumers to drug advertisements. This, in turn, could lead to “increased 
costs in terms of time, inconvenience, and out-of-pocket expenditures for a visit.” (Calfee, 2002). 
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Nevertheless, proponents countered that out-of-pocket drug expenditures could actually 
decrease, since health insurance typically covers the cost of prescription drugs (Calfee, 2002).  
Prescription drug advertising is unique in that the advertised product cannot be purchased 
without cooperation from a third party—a doctor, pharmacist, health insurance provider, or a 
combination of these actors. As a result, to stimulate sales pharmaceutical drug companies must 
be particularly persuasive and encourage the consumer to seek out more information, talk to a 
doctor or pharmacist about the drug, and pass on information about the drug to friends and 
family—activities that disseminate information about and interest in the product and secure a 
vehicle to complying with the advertisement and purchasing the drug (Becker, 2005, p. 442). 
 
B. Impacts 
 As seen in the preceding section, in the 1980s and 1990s the stage was set for direct-to-
consumer drug advertisements to explode into the marketplace. As partially anticipated, and 
feared, by critics of this approach, this change caused a variety of repercussions experienced by 
the different parties involved in health care and the pharmaceutical drug industry.  
 
 1. Patients 
 The single greatest concern regarding direct-to-consumer advertising has centered on the 
potential impact of this form of advertising on patients. First and foremost, by giving consumers 
so much influence in making decisions regarding prescription drug choices, the most pressing 
concern is of patient safety (T’Hoen, 1998, p. 595). Potential dangers arise from the possibility 
that consumers will not be wholly rational when making decisions or diligent enough to seek out 
and understand information about a drug from a direct-to-consumer advertisement before 
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bringing it up with their doctors. The failure to identify or understand some serious health risks 
associated with a particular drug, for example, could pose a very serious risk to patient health 
(T’Hoen, 1998, p. 586).  
Studies have also found that individuals hold multiple misperceptions regarding FDA 
regulation of direct-to-consumer drug advertising and how valid and informative these 
advertisements in fact are. Studies have shown that many people believe drug advertising is 
“meticulously regulated” (Consumer Reports, 1996, p. 62). Gellad and Lyles (2007) found that 
50% of a sampled population believed direct-to-consumer advertisements are submitted to the 
FDA for approval before they are released. In addition, 43% believed only “completely safe” 
drugs could be advertised and 21% reported to believe that only “extremely effective” drugs 
could circulate advertisements for their products (Gellad, 2007, p. 475).  Clearly, there is a gap 
between FDA regulations and consumer comprehension of the policies. This becomes 
particularly problematic when patients trust the advertisements they see, which could lead to 
pursuing a prescription for a drug that is not necessarily safe.  
 An FDA survey found that 81% of respondents in a sample recalled having seen or heard 
a prescription drug advertisement in the preceding 3 months (Aikin, 2002). Other studies 
examined the effects of this high level of exposure to prescription drug advertising on consumer 
attitudes. One study found that media exposure leads to a heightened awareness of prescription 
drug advertising. This awareness, in turn, was found to be related to favorable attitudes towards 
prescription drug advertisements (Everett, 2001, p. 44). Interestingly, this study found print 
media advertisements were mostly strongly correlated with awareness and positive attitudes.   
 Some studies reported other favorable effects of direct-to-consumer advertising. One 
such study reports that consumers are more likely to initiate discussion with their physician 
 Wollstein 17 
 
concerning a particular drug they saw an advertisement for (Kaiser Family Foundation, 2001). 
This increased communication with a physician, another study argued, could lead to better 
diagnoses and better-suited treatment plans. The study also reported that individuals are by and 
large rational and thoughtful consumers, who are prompted by advertisements to seek out more 
information about advertised medicines and who place importance on features such as side 
effects, doctor’s recommendations, product strength, and previous personal experience when 
selecting a drug brand (Kaphingst, 2004, p. 520). On the other hand, some more problematic 
findings stemming from this study include the tendency also placed by consumers on more 
artificial product attributes, including pill color, brand name and advertising of the product in 
making drug decisions (Kaphingst, 2004, p. 522). These findings suggest that it cannot be 
assumed that the general population is educated, informed or rational enough to make mindful 
and sound decisions when it comes to determining medical treatments. The study even identified 
specific demographics particularly “vulnerable” to these unsound decisions—the youngest and 
oldest survey participants. The study warns that these age groups, who value brand name over 
personal experience, could be particularly susceptible to influence and persuasion by direct-to-
consumer advertisements (Kaphingst, 2004, p. 522). 
 Other studies have reported that a relationship exists between direct-to-consumer 
advertising exposure and inquiry about the specific drug from a physician or pharmacist (Perri & 
Dickson, 1988). One study found that attitudes about direct-to-consumer drug advertisements 
were related to the intention to seek more information about the drug (Williams & Hensel, 1995). 
Most significant of this series of studies, one conducted by Peyrot et al. (1998) found that direct-
to-consumer advertising influenced consumer knowledge and promoted requests of specific drug 
brands. 
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 Another study conducted by Roth found that some consumers inaccurately interpret 
advertised messages. The resulting false beliefs indicate that direct-to-consumer advertisements 
can misinform consumers either directly through inaccuracies spread by an advertisement or 
indirectly by reinforcing some false previously-held consumer knowledge. These findings are 
worrisome because they show that consumers do not necessarily make sound decisions when 
they don’t have full knowledge of a drug and its associated risks (Roth, 1996, p. 64).  
 Another significant cause for concern from direct-to-consumer advertisements is their 
potential to lead consumers to believe they may have a certain medical problem and, perhaps 
even worse, that there is an appropriate pharmacological solution to their ailment that must be 
pursued right away (Woloshin, 1991, p. 1143). The effect of direct-to-consumer advertisements 
may suggest, then, that this form of advertising promotes the medicalization of common 
symptoms. Conditions such as sneezing, hair loss, or being overweight—which patients may be 
able to manage without a physician—now become targets of drug brands and advertisements. 
The danger associated with this shift is of blurring the boundaries of medicine and the validation 
of the process of medicalization through the prescription requirement of these advertised 
pharmaceuticals. Through this process, a consumer quickly turns into a patient who needs to be 
treated for some condition (Woloshin, 1991, p. 1143).    
 
 2. Doctors 
 In addition to impacts experienced by patients, direct-to-consumer advertising has also 
had an especially pronounced effect on physicians. Doctors have been coping with changes 
brought on by this new form of marketing and have been forced to face off with consumers who 
arrive at their appointments armed with often-questionable, incomplete information from 
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advertisements. The main impacts of this trend can be divided under two headings—patient-
physician interactions and physician prescribing behaviors.  
 
  a. Patient-physician interactions 
 The relationships between patients and their physicians have been significantly affected 
by the direct-to-consumer advertising trend. With products now marketed directly to the patient 
and an increasing amount of available information about, and exposure to, drug advertising, one 
third of consumers who remember seeing an advertisement for a brand-name drug report to have 
asked their physicians for a specific prescription (Aikin, 2002). Similarly, 92% of physicians in a 
2002 FDA survey reported discussing an advertised drug with their patients. These respondents 
also indicated that the conversation was initiated by the patient (Aikin, 2003). Among those 
patients who discussed a direct-to-consumer advertisement, 25% received a new diagnosis 
following their appointment with their doctor (Weissman, 2003). These findings suggest that the 
direct-to-consumer advertising strategy has proved costly in terms of a physician’s time with a 
patient, which now must be spent reeducating the patient and adjusting his/her expectations from 
an advertised drug. This type of advertising has also detracted from the discussion of patient 
symptoms, available treatments, and the context of a patient’s illness in favor of pharmaceutical 
solutions and brand drug information (Wilkes, 2000, p. 113).  
 In addition to talking with their physicians about prescription drugs seen in an 
advertisement, patients may go as far as insisting on an inappropriate treatment because they are 
particularly persuaded by promotional materials they may not fully comprehend or that “come 
from an industry that has not been historically honest about the medical value and safety of its 
products.” (Bell, 1999, p. 446).  Doctors are becoming increasingly concerned and distrustful of 
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these advertisements, perhaps because of their own experience with pharmaceutical companies 
using biased or unbalanced data to promote their products (Wilkes, 2000, p. 117).  
This change not only endangers the professional dynamic between doctors and patients, 
but requests for drugs seen in an advertisement could go as far as to divert the physician’s 
attention away from the patient’s other, and perhaps more pressing, medical needs. However, 
patients appear to be particularly insistent on discussing advertised drugs and obtaining 
prescriptions to treat their various ills. Bell’s study (1999) found that if refused a prescription for 
an advertised drug, patients would, first of all, be disappointed with the decision. Moreover, the 
vast majority of respondents believed they would exhibit at least one negative reaction to their 
physician’s denial of prescription (Bell, 1999, p. 450). Respondents reported almost as frequently 
that they would accept their physician’s decision, but a significant percentage of others claimed 
they would attempt to persuade their physician to reconsider his/her refusal. A few respondents 
even went as far as to say that they would seek to obtain the prescription from another doctor or 
else would terminate their relationship with the physician should he/she refuse to provide them 
with a prescription (Bell, 1999, p. 450).  
 Not surprisingly, physicians are hard-pressed to contend with these changes. In a study 
conducted by Gellad et al. (2007), 18% of physicians reported to believe that direct-to-consumer 
advertising led to problems in interacting with patients, including increased time to correct 
patient misperceptions, requests for unnecessary drugs, and requests for pharmacological 
treatments for conditions that could be managed without medication. As a result of patient 
pressure, doctors report to feel frustration and a sense of loss of control in their profession. 
Doctors also report to dislike appearing ignorant, poorly informed, or generally unhelpful in 
refusing to provide a prescription for a requested drug (Wilkes, 2000, p.117).  
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  b. Prescribing behaviors 
 In addition to the shift in relationship dynamics between physicians and patients, 
significant changes in physician prescribing practices have been noted as well. Some of those 
most concerned by the effects of direct-to-consumer advertisements assert that by affecting 
physician’s prescribing practices, this form of marketing cancels out its alleged public health 
value (Hollon, 1999, p. 382). While it has been argued that physicians serve as gatekeepers for 
this system of disseminating prescription drugs by ensuring that no drug abuse occurs, data 
documenting current physician prescribing behaviors has led to the questioning of this assertion 
(Hollon, 1999, p. 384). In a Consumer Reports (2003) survey, doctors wrote significantly more 
prescriptions for those who requested them than for those who did not. Clearly, physicians are 
influenced by patient demands, and are susceptible to pressures exercised by these individuals. 
As many as half of physicians in an FDA survey reported to have felt at least some pressure to 
prescribe a particular drug as a result of direct-to-consumer advertising (Gellad, 2007, p. 477).  
 A study conducted by Schwartz et al. (1997) found that some physicians prescribed drugs 
“at a rate far greater than that warranted by scientific evidence of their effectiveness.” When 
asked about the reasons behind their prescription decisions, doctors most commonly cited patient 
demand. Moreover, a study conducted by Petroshius et al. (1995) found that physicians are prone 
to prescribe less effective or efficient medications in order to appear more responsive to the 
requests of their patients. More recent studies have corroborated previous findings that patients 
are more likely to obtain a prescription when they arrive at a physician’s office expecting one 
from their doctor (Hollon, 1999, p. 383).  
 Wollstein 22 
 
 While it cannot be expected that doctors should be immune to marketing efforts, 
presumably their education and medical knowledge makes them more discerning and skeptical of 
such persuasion techniques (Hollon, 1999, p. 383). Nevertheless, the frustration and impatience 
doctors have been feeling as a result of this marketing shift, combined with growing pressure 
from patients, has led to an increased volume of prescriptions of brand-name drugs, even against 
some physicians’ better judgment (Consumer Reports, 2003, p. 35). As many as 50% of doctors 
in a Consumer Reports (2003, p. 34) survey reported that it was unlikely or at best only possible 
they would have prescribed a requested drug if they were basing their decisions solely on their 
own judgment, barring patient input and pressures.  
 
 3. Healthcare organizations, insurance companies 
Since direct-to-consumer advertising is still a relatively new strategy, it is difficult to 
generalize or forecast its precise effects on health care and prescription-filling costs. There is no 
doubt that direct-to-consumer advertising has caused some changes in the pharmaceutical drug 
market; the U.S. Government Accountability Office reported that dramatic spending increases 
have been recorded for advertising pharmaceuticals as a result of increased drug use among the 
general public (Gellad, 2007, p. 478). This finding indicates that direct-to-consumer advertising 
is succeeding in stimulating pharmaceutical demand (Hollon, 1999, p. 383). Some drugs that 
have been carefully marketed have managed to significantly improve their market share, 
primarily thanks to extensive use of direct-to-consumer marketing techniques (Calfee, 2002). 
These techniques certainly pay off: in a 2002 GAO report it was estimated that every 10% 
increase in direct-to-consumer advertising for a drug brand resulted in a 1% increase in sales of 
that particular product (Gellad, 2007, p. 478).   
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Serious concerns have also been raised about the increased financial burden brought 
about by the (arguably excessive) prescription of newer brand pharmaceuticals over generic, 
cheaper drugs fulfilling the same function as their pricey counterparts (Consumer Reports, 1996, 
p. 62). Gellad et al. (2007, p. 479) report that prescription drug costs are “one of the fastest-
growing segments of health care.” There is significant potential to save billions of dollars simply 
by substituting back generic drugs for the brand-name equivalents that have replaced them 
(Gellad, 2007, p. 479).  
In addition to the direct costs incurred from filling brand-name drug prescriptions in 
increasing demand, direct-to-consumer advertising also raises health care costs more indirectly. 
Increased consumer interest in advertised drugs leads to more office visits and more costly (and 
possibly unnecessary) tests (Wilkes, 2007, p. 114). While some very expensive, specialized 
drugs could be cost-effective in the sense that they may be able to prevent long, invasive, and 
costly procedures such as surgery, most advertised drugs treat only mild, low-risk conditions. As 
it is, these types of drugs typically do not show a favorable cost-effectiveness ratio (Wilkes, 
2007, p. 122). 
 
C. Advertising  
As can be seen, the trends started by the shift in pharmaceutical advertising to address the 
patient directly have the potential, and have already begun, to cause significant, and alarming, 
changes in American society. Consumers are now at risk of receiving unclear or incomplete 
information about potent medications; relationships between patients and doctors have become 
strained and focused more on discussing drugs seen in advertisements rather than patients’ more 
pressing health conditions; physicians have begun to feel frustrated, resentful, and a loss of 
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efficacy in their own profession while changing their prescribing behavior to accommodate 
patient requests even despite their own professional judgment; and health care costs are projected 
to increase dramatically as generic medicines are being replaced by expensive brand-name 
pharmaceuticals. With these implications in mind, discussion can now proceed on to an 
examination of the advertising messages that have facilitated the consequences discussed 
previously. Many studies have been conducted evaluating the content elements of direct-to-
consumer pharmaceutical advertisements. Using different approaches, many have ascertained 
and warned that the educational value of this form of advertising is, as feared, debatable, and that 
the risk potential, stemming from inadequate information and misleading statements, is high. 
Overall, scholars seem to agree that direct-to-consumer advertisements are powerful, persuasive 
messages that are designed to sell a product and are not necessarily safe for the lay public. In 
addition, these ads appear not to fulfill their educational purpose. 
A study by Kaphingst (2001) undertook a content analysis of 23 direct-to-consumer, 
product-specific television prescription drug advertisements. The study determined that a 
majority of ads used both medical and lay terms to describe medical conditions. This finding is 
particularly worrisome considering the different levels of literacy in the average American 
population. Individuals with more limited literacy skills may have less background information 
about the drug or condition they see in an advertisement, and may not understand medical terms 
and jargon used in ads to communicate information. While the FDA urges pharmaceutical 
companies to use common language and easy-to-understand descriptions in their advertisements, 
it is evident that companies do not adhere to this requirement, at the potential expense of the 
consumer who is given incomplete or confusing information (Kaphigst, 2004, p. 518). 
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Another study by Kaphigst et al. (2004) examined the reading difficulty of the 
supplemental text materials (magazine ads, web sites, and brochures obtained through toll-free 
numbers) provided by pharmaceutical companies. The study found that all materials, save one, 
exceeded the maximum eighth-grade reading level recommended for use in literature aimed at 
the general public, and concluded that college-level reading ability is necessary to read and 
adequately comprehend the materials (Kaphingst, 2004, p. 144). Features including the 
presentation of extensive information not essential for consumers, lack of summaries of main 
concepts, use of complex syntax and medical jargon, lack of visual aides to summarize main 
points, and use of small text and a crowded layout were all identified to make actually obtaining 
additional information about a drug from these supplemental materials exceedingly difficult 
(Kaphingst, 2004, p. 145). Although the FDA’s adequate provision requirement is designed to 
ensure that consumers have access to product information, this data are presented in an 
unappealing and incomplete manner in drug advertisements and in an unclear, crowded format in 
text materials.  
A Consumer Reports (2003) content analysis of pharmaceutical advertisements found 
that while the majority of ads were judged to be factually correct and backed by scientific 
evidence, many left out important information that was only available in fine print. A study 
conducted by Woloshin et al. (1999) analyzed the content of 67 advertisements and found that 
most ads describe the benefits of a medication in vague, qualitative terms that remain largely 
unsupported throughout the advertisement. Consumer Reports (2003) found that only half of 
advertisements analyzed conveyed important information about a drug’s risks and side effects in 
the main promotional text of the advertisement. Moreover, less than half were honest about a 
drug’s efficacy. Doctors were consulted during this study and noted omissions, exaggerations, 
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and other problems in many of the advertisements. One of the major problems with the ads was 
the brief summary, which was characterized by “medical jargon and tiny print” (Consumer 
Reports, 2003, p. 36). Even though the information provided may have been accurate, reviewers 
doubted that consumers would take the time to “wade through it.” (Consumer Reports, 2003, p. 
36).  
Consumer Reports (1996) conducted a second content analysis of drug advertisements 
and coded for the ads’ educational benefits and quality by looking at variables such as use of 
medical jargon, placement of key information, print size, and comprehensiveness of the 
advertisement. The study identified a variety of misleading messages (one or more) prevalent in 
direct-to-consumer advertisements. These included omitting, minimizing, or obscuring a drug’s 
risks; inadequate, incorrect, or inconsistent labeling information; false, misleading, or 
unsubstantiated efficacy claims; false, unsupported, or misleading comparative or superiority 
claims; promotion of approved drugs for unapproved purposes or patient populations; promotion 
of unapproved, still-experimental medications; false or misleading information given to 
physicians by drug representatives or paid speakers (Consumer Reports, 1996, p. 63).  
A study by Kaphingst et al. (2004) found that television advertisements spent more time 
describing the benefits of a drug than its risks. This finding suggests a violation of the FDA’s 
“fair balance” requirement. A content analysis conducted by Roth (1996) also found that as 
many as one third of advertisements failed to present a fair balance of benefit and risk 
information. In addition, most of the advertisements omitted information on inappropriate uses of 
the drug and clear directions for proper usage (Roth, 1996, p. 72). Lastly, more complete product 
information (through a website, toll-free number, etc.) was only available in text, calling into 
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question drug companies’ compliance with FDA regulations requiring that “adequate provision” 
is made for providing product information.  
Kaphingst et al. (2004) also found that some advertisements lacked important contextual 
information to clarify the risks of an advertised drug. The study cites examples of statements 
such as “tell your doctor what other medications you are taking”—meant to indicate that the 
advertised drug is potent and should be taken in combination with other medications only upon 
approval to avoid adverse side effects—might not make those implications clear to the consumer 
(Kaphingst, 2004, p. 523). Only a minority of the examined advertisements adequately informed 
consumers that the drug might not work for every patient and most only described medical 
conditions and their treatments superficially. Just one of the 23 advertisements studied directed 
consumers to seek out more information about the drug (Kaphingst, 2004, p. 523). Instead, the 
majority of ads encouraged consumers to speak with their doctors.  
In addition to withholding important information and directing consumers to speak with 
their physicians, direct-to-consumer advertisements were shown to contribute to the 
medicalization of modern society by encouraging consumers to seek pharmacological treatment 
for common ills. A study conducted by Woloshin (2001) found that 39% of the advertisements 
studied in a content analysis encouraged people to consider a medical cause for common 
symptoms. A Consumer Reports (2003) survey also found that ads do not mention non-drug 
therapies for the same condition treated by the advertised drug.  
In an analysis of drug advertisement texts, Kaphingst et al. (2004) also found that many 
ads presented risk information in one continuous segment rather than interspersing information 
throughout the body of the text. This is problematic when previous studies, such as one 
conducted by the FDA (1980) showing that ads where risk information was presented in one 
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segment by a different announcer than the narrator of the advertisement were less persuasive 
than those that integrated warning information throughout the ad, are taken into account. A study 
by Wilkes et al. (2001) corroborates this argument, concluding from its own content analysis that 
direct-to-consumer advertisements tend to play up the positive features of a drug while 
downplaying its negative or unknown aspects, accomplished by mentioning less favorable effects 
last, using subheadings to emphasize benefits, and “burying” side effects within the body of the 
text.  
Kaphingst et al. (2004) also found that advertisements used only positive or neutral visual 
images while presenting important drug risk information. Further, Woloshin (1999) determined 
that 67% of advertisements coded made emotional appeals to consumers. The most common 
appeal was the desire to “get back to normal”. Other appeals focused on a feared outcome 
(Woloshin, 1999, p. 1143). From their content analysis of drug advertisements, Wilkes et al. 
(2000) found that the most common appeals to consumers included claims of effectiveness, 
symptom control, innovativeness, and convenience. The study also drew a parallel between 
advertisers’ tendency to use “new and improved” claims to sell generic products and the 40% of 
ads that used innovativeness as a compelling selling factor for pharmaceuticals. While marketing 
techniques must be adjusted to promote a product that involves as many risks and possible 
adverse side effects as pharmaceutical drugs, they are not eliminated altogether. Accordingly, 
Wilkes et al. (2000, p. 122) warn that “when it comes to drugs, what is new is not necessarily 
better and could even be more risky.”  
Consumer Reports (1996, p. 62) identified themes of persuasion used in drug 
advertisements, grouped into categories, including: “optimism reigns”, in which ads imply drugs 
are 100% effective for everyone; “the good mother”, harping on mothers’ obligation to their 
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children and implying that mothers who do not use drugs are guilty of neglect; “you don’t say”, 
ads in which only the fine print contains relevant information about drug potency and efficacy; 
and “all you need is drugs”, in which the ad neglects to mention that lifestyle or behavioral 
changes can often solve the problem. This reliance on emotional cues and themes and the 
dissonance between visual and auditory stimuli could both detract from rational decision-making 
on the part of the consumer as well as undermine the perception of risk for the advertised drug, 
and casts into doubt the advertisements’ “fair balance” provision (Kaphingst, 2004, p. 144). 
Cline et al. (2004) conducted a content analysis of direct-to-consumer advertisements 
using a slightly different approach. This study tested the assumption that the direct-to-consumer 
form of advertising uses social cognitive processes to influence consumer behavior. Based on 
this premise, the study found that direct-to-consumer advertisements use models with whom 
consumers identify and “whose personal features, activities, depictions, and products are 
associated with rewards that function as motivations.” (Cline, 2004, p. 152). Models in these 
advertisements possessed positive personal characteristics such as “healthy”, “active” and 
“friendly”, which consumers are likely to identify with and emulate. In addition, the study found 
that 90% of ads depicted some form of identity rewards, with almost 40% of ads actually 
depicting models as physical beneficiaries of these rewards (Cline, 2004, p. 152). The study 
identified both explicit and implicit visual cues that were used to convey strategies for the 
consumer to achieve those rewards. Given such relatable models, Cline et al. warn, consumers 
are likely to base their health choices on the favorable outcomes they see in an advertisement 
instead of on objective reasoning. 
Cline et al. (2004, p. 136) also found that direct-to-consumer advertising tends to 
reinforce stereotypes. The study demonstrated that advertisements featuring only women tended 
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to focus on stereotypical “women’s issues”, namely women’s reproductive capacity and 
psychiatric disorders. In addition, advertisements featuring African Americans were dominated 
by HIV/AIDS.  The study also found that despite the plethora of serious medical conditions 
affecting older adults, only 13% of the ad sample depicted elderly subjects (Cline, 2004, p. 138). 
The study concluded that direct-to-consumer advertising tends to rely on, and enforce, 
stereotypes relating to gender, race, and age.  
 
Multiple studies have examined the content of direct-to-consumer advertisements using 
varied approaches. While it is clear that drug information should be independent, reliable, and 
thorough, drug advertising is “none of these things.” (T’Hoen, 1998, p. 596). Most academics 
now agree that the educational benefit of the ads is moderate at best and the quality of 
information presented is poor (Hollon, 1999, p. 382). Researchers largely concede, as 
summarized succinctly by a Consumer Reports (2003, p. 36) survey, that “advertisements are not 
public service messages—they’re meant to move goods.”  
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Research Questions 
To add to the existing body of literature examining the direct-to-consumer advertising 
strategy, this thesis aims to address the following research questions: How do advertisers make 
pharmaceutical drugs an attractive commodity to patients? What kinds of persuasive tactics and 
cues are used to achieve compliance (i.e. sales)? How do advertising agencies create successful 
marketing campaigns promoting drugs to consumers who may not need them? Studying and 
breaking down the persuasive elements in this type of advertising will not only enhance the 
understanding of communications studies scholars of what elements make drug advertisements 
persuasive, but can serve as an important basis for future studies and policy suggestions to 
eliminate the threats posed by pharmaceutical companies appealing directly to poorly-informed, 
but eager consumers. This study will examine the questions posed above using a subset of ads 
treating for cardiovascular conditions collected from popular magazines. This thesis serves as an 
illustrative case study of direct-to-consumer advertising techniques. 
  
 




Textual analysis was conducted to identify the features and persuasive strategies utilized 
in direct-to-consumer drug advertising campaigns. Campaigns were selected based on the health 
condition treated by the advertised drug, that drug’s popularity in the pharmaceutical market, and 
the medium in which the ads were delivered.  
 
A. Campaign selection 
The top-treated medical conditions of American patients are, unsurprisingly, also among 
the most expensive to treat (UPI, 2008). Estimates of the costs of the top 10 medical conditions 
in the United States stand at over $500 billion. The most prominent, and expensive, condition 
among these is heart disease. 
 
Thorpe et al. 
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Therapeutic Class Value ($bn)  % of Total  Growth vs. 2005 
Cardiovascular  100.8  17%  7%  
Central nervous system  99.9  16%  8%  
Alimentary tract and metabolic  73.6  12%  9%  
Anti-infectives (bacterial, viral, fungal)  61.4  10%  3%  
Respiratory  40.1  7%  6%  
 
Pharmaceuticals World Market  
Cardiac disease is also the leading cause of deaths worldwide (Thorpe, Florence & 
Joscki, 2004). Cardiovascular disease refers to conditions affecting the heart’s ability to function 
properly. Since a disruption of blood supply to any part of the body can cause severe tissue 
damage, cardiovascular conditions are particularly deadly. As such, an entire industry dedicated 
to treating these conditions has sprung up. In spite of research, technological, surgical and 
pharmacological innovations, and an increased social consciousness of cardiac disease, however, 
people continue to lead unhealthy lifestyles that put them at risk of developing heart disease. 
Since heart disease develops over a long course of time, it is often difficult to prevent entirely 
and explains the steady reliance on pharmaceuticals once a diagnosis is made and treatment 
begins. Heart conditions were selected for analysis in this study following the rationale that the 
more prevalent among the population and expensive to treat, the more likely that drug companies 
would compete to penetrate into that market and establish a market share. 
Specific drugs treating for heart disease were selected on the basis of their market 
success. Leading the drugs in this category is Pfizer, Inc.’s cholesterol-reducing Lipitor, the 
world’s best-selling drug, which reportedly ran $244.4 million in advertising costs in 2009 
(Associated Press, 2010). Selection of drug brands for study was based on the assumption that 
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the more successful and market-dominating a drug is, the more likely it is to be advertised and 
widely available to the public through mainstream communication channels. Both Lipitor and 
Zocor, another cholesterol-controlling drug, were listed in the top 10 list of prescription drugs 
that contributed most to the increase in pharmaceutical spending (National Institute for Health 
Care Management, 2000). Lipitor and Zocor are joined by Pravachol in leading the cardiac 
treatment drugs, accounting for approximately 85% of the $6 billion market (Spain, 1999).  
With these considerations in mind, advertising campaigns were selected on the basis of 
the print publication in which they were found. Since heart conditions affect both sexes 
indiscriminately, advertisements were selected from magazines that do not appeal exclusively to 
one sex. Magazines were selected on the basis of their popularity, calculated by circulation 
numbers. The justification for selecting popular publications was the increased probability of 
encountering advertisements for market-leading brand-name drugs in commonly-consumed, 
general-audience venues.  
Most Popular Magazines in 2010 (by circulation):  
1 Better Homes & Gardens 
2 Reader's Digest 
3 Game Informer 
4 National Geographic 
5 Good Housekeeping 
6 Woman's Day 
7 Family Circle 
8 Ladies' Home Journal 
9 People Magazine 
10 Time Magazine 
11 Taste of Home 
12 Sports Illustrated 
13 Cosmopolitan 
14 Prevention 
15 Southern Living 
16 Maxim 
17 O, The Oprah Magazine 






22 Martha Stewart Living 
23 ESPN, The Magazine 
24 Newsweek 




B. Artifact description 
 Following the screening process described above, campaigns for Lipitor, Zocor, 
Pravachol, Vytorin, and Plavix were selected from the University of Michigan’s microfilm 
archives of Reader’s Digest, People Magazine, Time Magazine, and Newsweek from the years 
1995-2010, when direct-to-consumer print ads became most prominent in the chosen 
communication channel. Approximately 50 ads—about 10 distinct advertisements for each of the 
drugs selected for study—were identified and make up a comprehensive body of evidence for 
analysis. A brief description of the campaigns follows, and the advertisements themselves can be 
found in the appendix section. Collectively, despite varying layouts, the advertisements are all 
text-heavy and feature accessible, relatable models. 
 
 1. Lipitor 
 Lipitor has been the world’s leading cholesterol-reducing drug, as well as the highest-
selling prescription drug, since 1998 (Associated Press, 2010). Lipitor contains an enzyme 
blocker, known as a statin, to help lower cholesterol and triglyceride fats in the blood and 
ultimately prevent strokes and heart attacks (Mayo Clinic, 2010). Between the years 1995 and 
2010 Lipitor was marketed through two main print ad campaigns: in the first, the layout of the ad 
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is dominated by text and an enlarged image of a trusted, credible source—a physician, inventor 
of the artificial heart, or a heart attack survivor. The copy of the ad gives straightforward, factual 
information about the product and urges the consumer to consult their physician about the drug 
(see Appendix A1). The second part of the campaign, running concurrently with the first, is less 
obviously a drug campaign, featuring relatable models—people of all ages, races, and 
appearances—with numbers representing personal statistics, their cholesterol numbers, and the 
impact of Lipitor on these scores (see Appendix A2). 
  
2. Zocor 
 Zocor is another leading brand of cholesterol-lowering statins. Like Lipitor, it helps lower 
cholesterol and fats in the blood by reducing the liver’s cholesterol production activity (Mayo 
Clinic, 2010). Zocor also had two major advertising campaigns from 1995-2000. The first 
campaign features classic family memories—a wedding, a grandparent playing with a 
grandchild, an aging couple in an embrace—accompanied by copy urging patients to manage 
their cholesterol numbers to arrive at these life milestones (see Appendix B1). The second 
campaign, running concurrently, shows individuals in different challenging situations, like cold 
weather or a difficult hike, and the precautions they take to stay healthy. The copy of the ad then 




 Rounding out the top-3 selling cholesterol-lowering medications is Pravachol, a statin 
which reduces the amount of cholesterol produced by the liver to decrease the risk of heart 
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disease and stroke (Mayo Clinic, 2010). Pravachol’s print advertising campaign focuses on 
“average” figures partaking in different activities. Each individual states that he/she eats right 
and exercises, but that those safety measures are not enough to prevent a heart attack. The rest of 
the ad is text-heavy and informative, like most other advertisements in this category (see 
Appendix C). 
 
 4. Vytorin 
 This drug is manufactured by Merck, the same company that produces Zocor. Vytorin 
combines the main ingredients of Zocor with another drug, Zetia, to reduce the absorption of 
cholesterol in the intestines (Mayo Clinic, 2010). Vytorin’s advertising campaign takes a lighter 
approach to treating high cholesterol, rejecting the serious tone of other drug ads in favor of a 
more humorous take on the main contributors to high cholesterol—diet and family history. Each 
ad in the series features a slightly parodied elderly figure representing an individual’s family 
history as well as a typical high-cholesterol food, like a hamburger, French fries, or a club 
sandwich. Large text below the images compares Vytorin to other market leaders and 
emphasizes the dual efficacy of Vytorin against the sources of high cholesterol (see Appendix 
D). 
 
 5. Plavix 
 Plavix helps prevent future strokes, heart attacks, and artery blockages in patients with a 
history of cardiovascular problems by preventing blood clots from forming in blood vessels 
(Mayo Clinic, 2010). Plavix has not had a consistent advertising campaign in the years 1995-
2010, and the advertisements show some variation in appeal tactics. Collectively, however, the 
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ads employ more sinister images and slogans than their competitors. With images such as a 
hospital “Emergency” sign displayed backwards, suggesting that the consumer is already inside 
the emergency room; a strong and formidable construction worker who, the ad suggests, is still 
susceptible to heart disease; or simply the word “Clot” in large, bold face letters, the ads are 
slightly intimidating and very direct. Most importantly, the word “clot” is featured prominently 
in every advertisement, sometimes even serving as the main visual element in the ad (see 
Appendix E). 
 
C. Textual Analysis 
Textual analysis was conducted in the effort to examine the persuasive techniques used 
by pharmaceutical drug companies to advertise products to a newly-empowered, medically 
uneducated consumer base. The analysis itself was fashioned from several textual analysis 
protocols, used together to complement each other and compensate for structural differences.  
While this analysis is primarily a textual one in nature, overarching guiding questions 
were based on McGuire’s content analysis coding scheme, which considers: 
 
(1) Source factors, or the medium, genre to which the text belongs, and the context within 
which it is found, as well as the discourse community the text is a part of and the 
communicator’s characteristics (such as its credibility or trustworthiness);  
(2) Message factors, or the type of appeal and delivery style of the communication;  
(3) Channel factors, such as verbal versus nonverbal venues;  
(4) Receiver factors, or target audience characteristics—including age, education, and 
personality variables; and  
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(5) Destination factors, or the outcomes promoted by the communication, such as 
immediate versus long-term change (McGuire, 1984, p. 300).  
 
This method was used to compensate for some of the weaknesses of textual analysis, 
which, used alone, does not take into consideration factors external to the message itself. These 
factors, as outlined by McGuire’s model, are important for a more thorough and holistic 
understanding of the direct-to-consumer strategy and the kinds of messages that are the result of 
this movement’s influence. This study made significant efforts to control for source, channel, 
receiver, and destination factors, to be described in the data analysis section. The main emphasis 
of the analysis, however, rests with the message factors, which will be discussed in detail for 
every selected campaign individually.  
Interpretive textual analysis was used to achieve the objective of taking apart message 
factors and enhancing the holistic approach of content analysis to analyzing communications. 
This form of analysis allows a probe of implicit social meanings from a text. The following 
procedure, based on a combination of Daniel Chandler’s book Semiotics: The Basics and 
Roderick Hart’s Modern Rhetorical Criticism, was followed to conduct the textual analysis of 
the message factors, as outlined by McGuire’s model. 
This synthesized procedure analyzes the elements and style of the communication, taking 
into consideration:  
 
(1) The signifiers (cues, images, symbols) in the advertisements and their meanings;  
(2) The ad’s modality, or position—addresses the advertisement’s major claims and the 
validity and strength of the evidence used to support the claims as well as the clarification 
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devices and warrants used to strengthen the message—in addition to an assessment of the 
persuasiveness of the advertisement; 
(3) The class of paradigm, or pattern, the text belongs to—the values and contrasts that 
emerge as a result of the particular choice of medium, genre, and theme for the advertisement;  
(4) The syntax, or structure, of the text and a discussion of how sequential and spatial 
arrangement affects the text’s meaning;  
(5) The literary elements (metaphors, analogies, etc.) present in the text and how they are 
used to achieve the text’s intended reading;  
(6) The semiotic (meaning) codes in both the ad’s text and images and the relationship 
between these two components and the consumer—this analysis probes the cultural values and 
the preferred reading of the advertisement.  
 
Ad campaigns were analyzed individually and the analysis is detailed in the results 
section. A holistic, inter-campaign evaluation of recurring themes and elements is presented in 
the discussion section. 
 




 Analysis was conducted in order to identify and take apart the persuasive elements and 
strategies used in direct-to-consumer advertising efforts to market pharmaceutical drugs treating 
for cardiovascular conditions directly to consumers, bypassing physicians. While the messages 
themselves differed significantly in their approaches to persuasion, other elements of the 
communication process—specifically, the source, channel, receiver, and destination factors, as 
described by McGuire’s model—were held relatively constant. Though these factors were 
controlled, however, they nevertheless merit holistic examination and application to the 
individual campaigns examined in this section.  
 
1. Source factors 
The medium of the text was held consistent through the selection of popular magazines, 
as described in the methods section. All advertisements were selected from a collection of 
magazines chosen by both title and year published. As a result, the ad campaigns examined here 
all ran concurrently and in comparable (or identical) media channels. Time Magazine, Reader’s 
Digest, People Magazine, and Newsweek are mainstream, popular magazines appealing to all 
genders and races alike, an important consideration as heart disease affects individuals 
indiscriminately. As a result, heart health drugs were not expected to be marketed in specialty 
magazines appealing only to a very specific demographic. Instead, it was assumed that this 
selection of magazines would yield the greatest number of advertisements for this class of drugs.  
These magazines are also part of a similar discourse community, appealing to a 
particular, albeit wide, demographic. The magazines are comparable in the way that they 
combine news and current event stories with human interest pieces, celebrity tracking, and 
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shopping features, which demands a certain intellectual ability on the part of the publications’ 
consumer populations. As a result, the demographic that reads Time Magazine, Reader’s Digest, 
People Magazine, and Newsweek is generally educated, socially engaged, and young to middle 
aged (Pew Research Center, 2004). Although print advertisements are far-reaching, thanks to the 
considerable circulation numbers these popular magazines enjoy, they are constricted by space, 
size, length, and feature limitations imposed by print media. In a world where advancing 
technology makes it possible to reach consumers directly in their homes using highly interactive, 
personalized media, pharmaceutical companies have capitalized on television and online 
advertisements to lure consumers. Nevertheless, print advertisements remain an important source 
for study and are perhaps even more informative for the purpose of this analysis than their 
electronic counterparts because of said restrictions, which make them easier to analyze.  
Lastly, the selected magazines have the benefit of being long-standing and professional, 
and therefore are assumed to be credible sources of information for their readers. Advertisers 
must compete for these lucrative, and often very expensive, advertising spots specifically for that 
reason—readers who trust the publication they are reading will be more likely to trust the 
advertisements they see running in its pages (Pew Research Center, 2004). While advertisers use 
different tactics to emphasize their products’ credibility and trustworthiness, the publication in 
which the ad is running makes an important contribution to readers’ perception of the 
advertisements’ credibility. 
 
2. Message factors  
The one major element that was not controlled for in the screening process—and the 
main object of this study—is the message, or advertising campaign, itself. The type of appeal and 
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delivery style of the messages vary considerably, and shed light on the main research question of 
this study: how advertisers attempt to persuade potential consumers to seek a prescription for a 
brand-name pharmaceutical drug? Message factors were analyzed for every selected campaign 
individually, below. A more comparative analysis follows in the discussion section.  
  
A. Lipitor 
1. Campaign 1 (Appendix A1) 
The first branch of Lipitor’s major advertising campaign in the years 1995-2010 is neat, 
loaded with text, and straightforward. The spatial organization and elements included in the ad 
make it seem more informative than commercial, and lends a sense of credibility and expertise to 
the message conveyed by the communication. With the exception of a top bar dominated by a 
large, Lipitor-promoting quote and a figure—from Dr. Robert Jarvik, an inventor of artificial 
heart models to individuals who have survived heart attacks or strokes—the ads feature a lot of 
text arranged in a clear, minimalist design and featuring different text fonts. The advertisements 
are easy to read and have the appearance of a professional, scientific text. 
The choice of models for this series of advertisements lends credibility and humanity to 
the otherwise stark, somewhat intimidating text. As the endorsers featured in the ads assert that 
“[Lipitor] lowered my [cholesterol]” and “I never thought [a heart attack] could happen to me”, 
Lipitor’s effort to lower cholesterol and save lives is painted in an altruistic, concerned light. 
Although the models are clearly vulnerable, as they themselves have suffered from heart 
conditions or threats like high cholesterol, their weakness makes them all the more relatable and 
their success stories of “beating” cholesterol, avoiding a second heart attack or stroke, and 
determination to seek out a medication that will help them accomplish this goal make them 
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inspirational to consumers concerned with their heart health. The ads’ use of models whose 
careers are relevant to the cardiac conditions treated by the drug—like the inventor of the 
artificial heart—or whose experiences have inducted them into this particular community 
strengthens the credibility of the ads in several ways. First, the endorsers’ personal experiences 
of Lipitor use and knowledge of the drug makes them seem competent and trustworthy. Through 
their worried facial expressions, these spokespeople also seem to convey a deep concern for the 
heart health of the reader, who may be at risk of heart attack or stroke. The models’ and the 
accompanying text’s urging to find out more about Lipitor gives the ads a sense of goodwill and 
concern, implying that the pharmaceutical company has the best interests of the audience in 
mind. Lastly, the use of “real”, relatable models that resemble the average reader and whose 
testimonies are familiar to the targeted audience makes the message delivered by the ad 
particularly powerful. Overall, the use of relatable models in the campaign enhances the 
personalization and poignancy of the advertisements. In addition, the use of models with success 
stories, showing only favorable outcomes of using the drug, portrays the risk of heart attack or 
stroke as a serious, but manageable condition thanks to the availability of Lipitor.  
  The ads also assure potential consumers that Lipitor has been extensively researched, 
claiming that over 400 clinical studies have been completed in its evaluation. While this 
impressive statistic clearly is meant to imply that the drug is safe for use, the advertisements 
hedge around specifically calling the drug safe and do not provide additional information about 
its efficacy or potency. The avoidance of mentioning risks and side effects of the medication in 
the main body of the ad and its placement on the reverse side of the page—where fewer readers 
are likely to notice, or bother, to read it—is a classic feature of the direct-to-consumer strategy. 
Despite broad claims of effectiveness and assertions of safety, these are not backed by evidence 
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in the ads and although casting an illusion of reassurance, can be deeply misleading to the casual 
reader. 
In addition to the cues and images, which add credibility to the ads’ message and make it 
more relatable to consumers through the use of carefully selected models, the ads take a very 
clear position on what can—and should—be done to treat high cholesterol. The text and images 
of the ad strongly act as a call to action for those with high cholesterol “when diet and exercise 
are not enough”. Although the ads offer little evidence to support the claims made in the body of 
the text, the emphasis on rationality, information, and reason is evident throughout the ad, from 
the somber visuals to the minimalist, professional layout of images and text. The ad is persuasive 
because it manages to draw in the casual reader using emotional cues prompted by the models 
who claim they “trust their hearts to Lipitor”, and then continues to bombard the consumer with 
text and information that emphasizes the rational facet of the drug selection process. Hooked by 
the seemingly-trustworthy models and further drawn in by the abundance of information made 
available, the ads appear to aim to appeal to individuals who want more than a vague assurance 
of the drug’s efficacy. By providing information about the drug, advertisers make the ad 
particularly persuasive and Lipitor especially appealing. The use of motivational warrants, “ideas 
suggesting that some desirable end must be achieved or that some desirable condition is being 
endangered,” (Ehninger and Brockriede, 1963) in this fashion is particularly effective in luring 
and persuading an emotionally-based, but rationally-inclined individual. 
The advertising campaign fits into a value paradigm that emerges as a result of the 
choices of elements—texts, visuals, layouts—in the ads. The values of individualism and 
personal choice—so deeply ingrained in the American doctrine and work ethic—are very evident 
in the advertisements. Although lay individuals must consult their physicians to obtain a 
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prescription for a drug like Lipitor, the suggestion that the consumers themselves can seize 
control of their own destinies and actively work to improve their own health even when “diet and 
exercise are not enough” and they require supplemental pharmaceutical aid is very empowering. 
In addition, the respect for and trust in scientific research and rationalism are indulged in the 
advertisements by presenting information, although somewhat simplistically, to the consumer 
and giving the impression of respect for his/her intelligence and involvement in the decision-
making process in selecting a drug. The combination of consumer empowerment in both the 
emotional and rational dimensions is particularly powerful in stimulating interest in the 
advertised product. 
Lastly, the campaign also draws on “universal topics” (Wilson and Arnold, 1974) that 
add meaning to the advertisements and reflect the cultural values they promote. Perhaps most 
important in this campaign, the potency of Lipitor, combined with its capacity to change a 
patient’s health and the feasibility that this favorable change will occur, work to strengthen the 
ads’ message. The modern societal need for a pharmacological solution to all ills and the 
assurance of the product’s effectiveness and credibility—lent by the publication in which the ad 
appears, the major pharmaceutical company promoting the product, and the message elements 
discussed here—is satisfied and consumers are enticed to seek out a prescription for Lipitor from 
their doctors. 
2. Campaign 2 (Appendix A2) 
 The second part of the 1995-2010 Lipitor campaign is quite different in its approach to 
addressing consumers from its somber, text-heavy counterpart. In this series of advertisements, 
very “normal”, representative models—a family, a pair of twins, a young woman—are pictured 
smiling appearing relaxed and happy. The only other visual cue in the ads is a series of numbers 
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indicating some of the models’ characteristics, from height and weight to number of weekly 
workouts and apples eaten a day, as well as their cholesterol numbers. The message of the ads is 
very simple: high cholesterol is impossible to detect superficially, and can affect anyone. Even 
though the young woman is tall and thin—as the stated measurements prove—and is clearly 
beautiful and confident, she still has high cholesterol. Although the pair of twins pictured looks 
identical, weigh the same and have the same diet and exercise routine, one has high cholesterol 
while the other does not. In the family photo in which all members seem smiling and happy, 
three members have high cholesterol while a fourth does not.  Although these people are smiling, 
they represent the very real threat of high cholesterol and the risks of heart attack and stroke 
stemming from it. The only difference between the low- and high-cholesterol figures featured, 
according to the ad, is Lipitor—and, the ads seem to suggest, it can solve the consumers’ high 
cholesterol problem, too. 
 While the advertisers chose to use smiling, happy models, they in fact represent the 
ominous threat of high cholesterol and the increased risk of heart attack or stroke that 
accompanies it. This threat is even more alarming when considered in contrast with the 
seemingly obvious physical vitality and health of the subjects portrayed in the ads and further 
enforced by a caption in one of the ads that “high cholesterol doesn’t care who you are.” In 
response to these threats, the advertisements invite the consumer to let Lipitor help “rewrite 
history.” The ads take a very clear stance in addressing the risk of high cholesterol—for those 
who are unable to control their cholesterol with diet and exercise alone, the only solution is 
Lipitor. This position is supported by some encouraging statistics, which claim a 30-60% 
reduction in cholesterol numbers in patients who take Lipitor compared to those who do not, but 
as with the first campaign the claims are not well supported. This finding is somewhat 
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incongruous with Lipitor’s general tactic of appearing straightforward and forthcoming with the 
amount of information provided to readers. Especially in this subdivision of the campaign, there 
seems to be much more emphasis on emotional cues—such as the threat of high cholesterol to 
the happy family unit—than on factual information. The little text that is provided in the ad is 
dominated by authoritative, rather than substantive, warrants supporting the claims made in the 
ads. Instead of providing evidence to corroborate the claims made in the body of the text, the ad 
relies on the brand name’s credibility and perceived expertise to suggest that Lipitor is a suitable 
choice for any patient. 
 The ad invokes several paradigmatic values to support its message. Once again, in 
contrast to the previous campaign’s appeal to information and scientific rationality, in this 
campaign Lipitor’s advertisers elected to emphasize the importance of family bonds, health, and 
happiness—reinforced by the ads’ visual elements—and contrast these values with the 
vulnerability of mankind and the precariousness of health. This contrast is powerful because it 
taps into a very basic human fear of death, disease, and lack of control over circumstances. The 
advertisements’ offer of a tool to control these fears is particularly appealing to an audience 
whose emotions have been activated and that is being expected to make decisions and carry out 
actions, such as deciding that Lipitor is an appropriate drug and seeking out a prescription from a 
physician, not based entirely on information and rational reasoning but rather stemming from the 
fear of losing control, happiness, and health, as the ads ever so subtly suggest. 
 The layout of the ad and the structure of the text further reinforce the predominance of 
emotional over rational appeals in the campaign. The visual element in the ads takes up most of 
the space in the two-page spread. There is some dry, technical information provided on the 
bottom left page of the ad, printed in small, cramped text. On the right page, however, the reader 
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is provided with a short narrative that presents “the bad news”, or problem of high cholesterol, 
and goes on to suggest Lipitor as the solution to this problem and “the good news”. The 
exclusive portrayal of positive outcomes in the ad series—even though the featured models are 
clearly at risk for heart attack or stroke, they now have a solution for this threat—is enticing and 
once again ties into the ads’ overall appeal to emotion. Although surely the consumer realizes 
that it is unrealistic to expect total efficacy and success from taking the drug, the visual cues—
the smiles, the families, the encouraging cholesterol numbers of those models who take Lipitor—
threaten to outshine the fear of the drug’s failure to control the consumers’ high cholesterol. 
 Several semiotic codes can also be identified in the ads to achieve its intended message. 
The underlying emphasis on the existence of a solution for the problem of high cholesterol is 
especially prominent in the advertisements. The desirability of Lipitor as a tool to beating a 
common affliction (“2 in 3 adults who control their diets and exercise cannot lower their 
cholesterol enough”) is also evident in the advertisements. The promise of improvement after 
taking the drug and Lipitor’s potency and ability to reduce the threat of heart attack or stroke are 
also important in creating the impression that while the threat to health may be real, a solution is 
also readily available and accessible with a simple prescription from a physician. 
 
 B. Zocor 
  1. Campaign 1 (Appendix B1) 
 The Zocor campaign from 1995 to 2010 can also be categorized into two main efforts. 
The first features all sorts of sentimental, emotion-evoking, family-themed images. The ads 
portray images including those of a couple walking along a sandy beach, a grandfather with his 
grandson, a wedding scene, an aging white couple in a warm embrace, a mother and her son, and 
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a laughing elderly couple. Clearly, the advertisers made significant efforts to represent a wide 
variety of people within the target demographic. Although one of the two pages of the spread is 
loaded with text, several phrases throughout the body are bolded or highlighted. All are 
variations on the subject of the future and of the reasons to address the threat of high cholesterol: 
“It’s your future. Be there”, “I have a lot of good reasons for taking care of my cholesterol”, 
“where will you be when your grandson gets his first taste of the ocean?”, and “where will you 
be when your wedding dress walks down the aisle a second time?”. While the models are 
featured in obviously happy, loving scenarios, the accompanying text is ominous in its 
suggestion that this happiness is threatened by high cholesterol and heart disease, effectively 
changing the tone of the ads entirely. The contrast between the relatable scenarios portraying 
tender moments in an individual’s life and the bold, almost harsh declaration of the text that this 
happiness is at risk is particularly effective at eliciting an emotional response, especially from an 
older demographic—the main age group at risk for cardiac conditions—for whom these appeals 
might strongly reasonate. Suggesting that the individual has a major role in determining his/her 
future with slogans such as “how will you take care of your high cholesterol and heart disease?” 
the ads shift the responsibility to act from the physician onto the individual. By cueing an 
emotional response using such strong visual elements and in contrast with the almost-accusatory 
text, the advertisers draw in the now-panicked reader in search for a solution. 
 The ads’ modality is clear: the future is important, and is something to hope for and look 
forward to, but is constantly at risk. Luckily, according to the ads Zocor is not only effective, but 
can go as far as to save lives and ensure the consumer has reaches his/her future. This message is 
communicated through an informative, though not didactic narrative that turns the intimidating 
topic of disease and death into a more approachable and manageable experience for the lay 
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reader. Although there are not nearly enough substantive facts or statistics in the ads to reassure 
the reader that the drug itself is potent and effective, the narrative form of the text and its 
conversational flow are somewhat soothing and appealing to an intimidated reader. Nevertheless, 
the advertisements achieve credibility through the perceived competence of the pharmaceutical 
company and the drug itself “with more than 10 years of experience and 140 million 
prescriptions filled.” The strength of numbers presented here is compelling and increases the 
trustworthiness of the drug—if it was not safe and effective, 140 million scripts would not be 
issued for it. The advertisements make use of motivational warrants to support the major claims 
in the text, emphasizing the importance of securing one’s future and the possibility of doing so 
with the right medication. 
 The advertisement positions itself within the paradigmatic family common to 
communications in this particular market that rely primarily on emotional appeals—the 
importance of family, the emphasis on the future, and the threat presented by high cholesterol to 
these idyllic scenarios. By explicitly singling out the reader, with statements such as “it’s your 
future. Be there” and “how will you take care of your high cholesterol and heart disease?”, the 
ads also capitalize on the notion of control, self-determination, and possibility for change 
brought about by the individual. This call to action is effective in empowering and mobilizing the 
consumer, who is told that even things previously out of their control, like prescriptions for a 
pharmaceutical, are now accessible and within reach. The reader is given not only the power, but 
the authority and responsibility to take control of his/her health and future. And, according to the 
advertisements, Zocor is the solution to these very fears. 
 The syntax of the Zocor campaign is very significant. Because the reader is primed with 
such an aggressive onslaught of conflicting emotion—from the happiness in the images to the 
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threat of the bold slogans—the rest of the body of the text is important in guiding the reader 
towards the desired outcome of obtaining a prescription for the drug. The text itself is not overly 
technical or filled with medical jargon, but rather reads as a mild, even soothing explanation of 
the condition of high cholesterol and how Zocor offers the opportunity and the tool to address 
this concern. The text is informative and makes use of different font sizes and colors to 
maximize its effect. The result of these manipulations is a persuasive and calming advertisement 
that can placate and convince a now-worried reader whose emotions were triggered by the visual 
cues that initially catch the eye when skimming through magazine ads.  
 Optimism is an especially important value drawn on in the Zocor campaign. The 
suggestion that the individual has both the power and the opportunity to take charge of his/her 
future is powerful only when it is combined with the optimism and assurance that the effort will 
pay off and the reader will succeed in lowering his/her cholesterol and reduce risks of heart 
attack. This optimism is conveyed through visual elements, such as the image of the couple 
strolling on the beach, leaving behind two lawn chairs. The portrayal of the couple moving 
forward together is encouraging, soothing, and something many aging couples likely aspire to 
and hope for. The gentle suggestion by the text that Zocor is a potent and available solution to 
the problem of high cholesterol, which could devastate this idyllic future, acts as a powerful 
stimulant. 
2. Campaign 2 (Appendix B2) 
 The second approach by Zocor is a bit different. The ad series features models in 
challenging conditions, such as a woman prepared for a hike, a woman caught in the rain, and a 
man ready to shovel tall piles of snow, and points out all of the protective gear and precautions 
taken against threats like hunger, thirst, the cold, or the elements that are present in those 
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situations. The figures in the ads are dressed warmly in layers and heavy coats, the hiker carries a 
water canteen and a hiking stick, the woman is wearing a raincoat, boots, and an umbrella, and 
the snow shoveler is equipped with a wool scarf, waterproof gloves, down jacket, insulated 
pants, all-weather boots, and a large shovel. The models are clearly prepared for the kind of 
activity they are about to partake in, and the ad asks in bold letters, “what are you doing to 
protect your heart?”. With all of the effort expended to protecting one’s health and well-being, 
the ad seems to argue, why neglect the heart? Most importantly, what are you, the reader, doing 
about your heart health? The visual and prominent textual cues seem to imply that the 
responsibility for maintaining a healthy heart lies primarily with the individual, and, moreover, 
that even the efforts already undertaken by the individual are not sufficient to protect the heart 
from threats like high cholesterol. Listing the protections taken by the models in the scenarios in 
which they are placed serves as an important similarity cue, which strikes a cord with the ads’ 
target demographic, which presumably is concerned with its health and well-being and is 
motivated to maintain them. Further, the major claims in the advertisements are strengthened by 
a cited study, conducted in Oxford University, which found that Zocor “is the first and only 
medication proven to significantly reduce the risk of heart attacks and stroke.” From a visual and 
symbolic perspective, then, the ads are relatable, persuasive, and—unlike many campaigns in 
this category—seem to even be backed by some credible findings, which are cited in the body of 
the text and lend the drug additional credibility.  
 The manufacturers of Zocor take a clear position in the ads as they urges consumers to 
seek prescriptions for the drug: since health is clearly important and a priority, the ad appears to 
argue, the consumer is virtually obligated to explore the possibility of Zocor with a physician. 
Since Zocor can help where an individual’s own ability to self-protect ends, it is the 
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responsibility of the consumer to consider Zocor as a viable treatment option for high 
cholesterol. The argument is underscored using authoritative warrants, which attempt to show 
that the product is credible and emphasize that not only does the problem of high cholesterol 
exist and present a considerable threat to heart health, but that Zocor has a solution for it.  
 By aggressively singling out the individual as the major responsible player in the 
commitment to heart health, the advertisements further draw on paradigmatic values including 
the right to self-preserve, be proactive, and fight even against things that normal efforts—such as 
controlled diet and exercise—cannot prevent. The approach of giving the consumer a real-life, 
relatable example of situations in which individuals must prepare themselves against risks that 
cannot be avoided or controlled for serves as a powerful and effective analogy for supplementing 
a routine of self-care with medications like Zocor, which can help protect heart health. 
 The message of the communication is further reinforced by the layout and syntax of the 
advertisements. Dedicating half of the advertising space to the visual component of the 
communication is important, as the image is an important element in the persuasive capital of the 
ad and adds a more accessible, relatable dimension to the argument. In addition, the arrangement 
of the text on the second page of the feature is neat, not overcrowded or loaded with medical 
jargon, and features text of the same size. It is important to consider that in contrast with many 
pharmaceutical advertisements, which include important considerations for the promoted drugs 
in tiny, illegible print, this series of ads uses equal sized text throughout. While the targeting of 
the individual is obvious in both the visual element and in the bolded text, the rest of the ads’ 
content is treated as if of equal importance—from the description of the condition and the drug to 
its concerns and side effects. This feature may contribute to the ad’s overall credibility and 
perception of honesty, as though Zocor, unlike its competitors, is frank about its limitations and 
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is concerned enough with the well-being of its future consumers to provide all necessary 
information up front and is not seen as trying to “hide” or withhold this important information 
from the consumer. 
 This series of ads also makes use of several semiotic codes that clarify the preferred 
reading of the communication. First, the assertion that a solution to the threat of high cholesterol 
exists, and the importance of the individual’s educated involvement in making drug-selection 
decisions, is reinforced throughout the ads and encourages the consumer to take a more active 
part in his/her health. Second, the ads draw on the spatial relatedness of heart health to other 
medical conditions, such as diabetes, for which an individual may already be treated. The 
advertisers seem to imply that, just as shown in the visual element of the ads, taking precautions 
against all sorts of risks is necessary and can be extended directly to include heart health and the 
elimination of threats like high cholesterol that can contribute to these conditions. Another 
important element of the argument made by the advertisers relates to the desirability of Zocor as 
a drug of choice to treat high cholesterol. With “over 160 million prescriptions for Zocor filled to 
lower cholesterol,” the drug’s popularity and market success give the impression that while 
Zocor is a powerful medication used to treat a serious condition, it remains safe for the general 
population, who is indulging wildly in its consumption. These assertions perpetuate the 
assumption that there is a pharmaceutical solution for every health concern, perhaps even for 
those who do not suffer from particularly high cholesterol levels. But since “everyone is doing 
it”, the drug’s desirability capital increases dramatically and may influence a reader’s decision to 
pursue a prescription for the drug. The advertisements’ treatment of heart health as part of a 
bigger problem also relates to this concern. This genus-species cue works in conjunction with the 
shift in the attribution of responsibility from physicians to individuals to prompt the consumer to 
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seek prescriptions because he/she is placed under the impression that they have not only the 
right, but the responsibility to seek treatment for their medical concerns. The availability of a 
pharmacological solution and the perceived awareness and individual responsibility greatly add 
to the ads’ effectiveness and persuasiveness to a worried and unsure consumer. 
  
C. Pravachol (Appendix C) 
 From 1995 to 2010, Pravachol released a series of ads featuring models representing 
different demographics, from a middle-aged male woodcutter to a young female swimmer to an 
elderly man. The varied demographics that are represented make the ads more personable and 
relatable to a wide variety of consumers. The models also all wear a similar, faint smiling 
expression that at first glance is comforting and appealing. On closer examination, however, it 
appears that the models are not as jolly as the generic figures depicted in other campaigns within 
the pharmaceuticals category. Instead, the models look tense, worried, even a bit solemn. The 
most prominent text in the advertisements is a quote from the model, which posits “I eat right 
and exercise to control my high cholesterol. Why should I worry about a first heart attack?”. This 
statement suggests that the models, like the potential patients and consumers they represent, are 
somewhat naïve about a condition they may have that could be threatening their health and are 
helpless to either prevent or treat the condition. The ad featuring the elderly man states “Irene, I 
know how afraid you have been about having a stroke. So take some advice from your kid 
brother.” The ad uses emotionally-stimulating cues to suggest that the population is at risk of 
heart attack and lacks the information and education to prevent this threat. 
The worry expressed in the visual elements, manifested in the models’ concerned 
expressions, as well as in the prominent text of the ad, shed light on the pharmaceutical 
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company’s standpoint in the campaign. Unlike other campaigns that seek to empower the 
consumer and emphasize the importance of education and choice in the selection of a 
cholesterol-lowering drug, the advertisers for Pravachol seem to capitalize on the ignorance of 
the average consumer. The ads appear to suggest that Pravachol is the right choice for a 
consumer who, like the models depicted in the campaign, is worried about his/her health but is 
unaware or uneducated about the risks of heart disease. Since Pravachol, as the ad states, can 
“reduce the risk of a first heart attack up to one-third,” and “could help you live a longer, 
healthier life,” it is the “proven” solution to the threat of heart attack. The ads make Pravachol an 
appealing option for consumers by marketing it aggressively and achieve trustworthiness through 
the authority expressed in the text, which reassures consumers that Pravachol can treat even 
those problems the consumer was not aware of or informed about prior to seeing the 
advertisements. Advertisers made use of substantive and authoritative warrants in the ads’ 
informative, factual content. Having caught the attention of the reader, pointed out his/her 
ignorance of the threat of heart attack, and warning that even efforts to reduce cholesterol such as 
controlling diet and exercise are “still not enough”, the ads now provide the reader with text that 
is actually informative and educational about both the targeted condition and the drug itself.  
The advertisements make use of rationality cues and information to persuade a consumer 
initially reeled in using emotional cues. This is achieved primarily by positioning Pravachol as a 
credible source that the reader can trust. While the populace traditionally entrusts its health to 
physicians and health care professionals, the Pravachol advertisements attempt to establish the 
drug company as a competing, if not superior, authority figure. Unlike advertisements by other 
pharmaceutical companies, the Pravachol ads urge the reader to ask his/her doctor about the drug 
only in the very last sentence of the text. The advertisements try to minimize the influence of the 
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physician in the drug selection process and undermine the power of the physician to make 
health-related decisions for patients. Since the uninformed consumer cannot protect his/her 
health alone, as even the best efforts are “still not enough”, Pravachol offers an appealing 
solution backed by studies and statistics that appears credible and is accessible to the consumer. 
This appeal is further reinforced by the layout and effective organization of the elements 
in the advertisements. The clean, simple layout lends the ads a professional appearance. The text 
itself follows a logical, informative progression of addressing the question posited by the models 
in the ad, listing Pravachol’s strengths, and even explaining some of its side effects in the main 
body of the text. The text is all presented in one continuous unit and is of the same size 
throughout. The effort to appear fair and balanced in presenting information to the reader 
reinforces the drug company’s stance of altruistic concern for the unsuspecting, helpless 
consumer addressed in the ad. The informative part of the advertisements, in turn, indicates the 
company’s willingness to help the consumer and fosters trust in the brand. 
The ads’ text and images draw on several cultural values that shape the communication’s 
preferred reading. The degree of risk of heart attack is emphasized, invoking the very real and 
prevalent concern of modern American society with health. The ads also use Americans’ 
emphasis on hard work and individual self-determination to emphasize that even despite the best 
efforts, health cannot always be maintained without pharmacological intervention. The potency 
of Pravachol and the feasibility of its success are especially appealing to consumers who may be 
wary of their physicians but are concerned about their health. Lastly, the ease of the solution to a 
threat that even efforts such as strict diet and exercise regimens, which require significant self 
control and determination, cannot manage, is also enticing. 
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D. Vytorin (Appendix D) 
 The Vytorin advertising campaign between 1995 and 2010 had a very different approach 
to marketing the drug than its competitors. The ads follow an identical template, where a bold 
heading reads “Vytorin treats the 2 sources of cholesterol” and below it pictures of a typically 
high cholesterol food—like onion rings or cupcakes—and a silly photo of an eccentric family 
member are displayed side by side. This more humorous approach to the threat of high 
cholesterol, while indeed addressing the problem directly, does so in a lighthearted manner. By 
neglecting to show the actual patient (in model form), or victim, of the threat of heart disease, the 
advertisements appeal to an audience that may be afraid of poor health and, specifically, of the 
negative repercussions of high cholesterol. By spinning the ad in a more cheery and funny 
direction, the manufacturers of Vytorin contend that while heart disease is a scary prospect that 
must be treated, there is no reason to panic. The ads don’t need to show happy models who 
survived heart attacks or concerned models with high cholesterol waiting for a stroke to strike; 
the elimination of the “victim” model takes the human out of the equation. All that is left, 
advertisers seem to suggest, is the drug therapy solution offered directly in the ad. 
Below the images, a bolded sentence states Vytorin was proven to be more effective in 
lowering cholesterol than two of its biggest competitors in the category, Crestor and Lipitor, in 
clinical studies. The emphasis on the dissimilarity between Vytorin and its competitors, and 
Vytorin’s superiority over them, is an important element in the drug’s advertising strategy. None 
of the campaigns analyzed thus far employed the strategy of comparing the product directly to its 
market competitors. Instead of focusing on the condition and the patient, the ad focuses primarily 
on the product. The direct presentation of the drug may be more overt, even pushy, but in the 
context of the slightly comical advertisement it does not seem inappropriate.  
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The series of advertisements makes its superiority claims by making use of a recurring 
cue of the number two. By emphasizing that the drug treats the two sources of high cholesterol—
diet and genetic factors—Vytorin claims to be better than its competitors. The advertisements 
also feature two images that correspond to the two sources of high cholesterol, a comparison to 
two of Vytorin’s market competitors, and display the remaining body of the text in two columns. 
Moreover, in the body of the text the advertisers explain that Vytorin actually contains two 
separate cholesterol medicines in a single tablet. In modern American society, a “one-stop 
solution” is particularly appealing. With the busy lifestyles and numerous health concerns 
bombarded at individuals and overwhelming them every day, multitasking—and a pill that 
claims to treat two conditions simultaneously—is instantly enticing. Since two are perceived to 
be better than one, consumers are sure to be impressed by what Vytorin has to offer in relation to 
other cholesterol-lowering drugs. 
The credibility of the ads is reinforced by the “clinical studies” mentioned in the body of 
the text as well as the perceived potency of a drug containing two medicines in one pill. The ads’ 
message is very clear: Vytorin was proven to be more effective than its competitors alone, so it is 
powerful. Even though there is no reassuring image of a smiling model representing the 
successful use of the drug to overcome a threatening condition, the ads seem to belittle the 
seriousness of the condition by putting a humorous spin on the images in the advertisement. The 
ads appear to offer a simple, but extra-powerful, solution to a simple problem the consumer can 
even afford to laugh at. 
With this approach, the Vytorin advertisements position the brand in a paradigm class 
that is less common in the pharmaceutical drug advertising industry. Although health is clearly 
not something to joke about, the ads offer a different take on the health and drug discourse. Since 
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Vyotrin is offering a solution to the problem, it appears that advertisers felt that displaying it in 
less-serious terms would not be perceived as offensive or disrespectful. On the contrary, there 
may well be consumers who, tired of the traditional scare tactics used in advertisements of this 
sort, may find this approach refreshing and persuasive. While the threat of heart disease is real, 
there may be many who feel that presenting and discussing the topic without dramatizing it is no 
less effective than threatening consumers with an impending heart attack should they fail to 
obtain a prescription for a cholesterol-lowering medication. Instead, bringing humor into the mix 
and simplifying a frightening scenario makes it more accessible to a lay audience. 
The body of the text of the ad is also interesting. Unlike its more “serious” competitors, 
the Vytorin ads actually provide very little factual information. The text is restricted to the 
bottom third of the page of the ad, and wastes no time explaining the condition the drug treats for 
or its risks, jumping immediately to urging the reader to ask his/her doctor about Vytorin in the 
very first sentence. The rest of the text is devoted exclusively to singing the praises of the drug, 
once again comparing it to its leading competitors, and concludes with a very brief statement of 
the drug’s possible side effects. The size and arrangement of the text also echo this prioritization: 
from a giant statement that Vytorin treats two, not just one, sources of cholesterol, to a medium-
sized proclamation of supremacy over two leaders in the market, to a small-font mention of 
possible risks and side effects of the drug. Vytorin’s position seems to take a position not of the 
concerned philanthropist, but of the bold company marketing its product. 
The ads are persuasive because they draw on some very prevalent, current societal 
values. The competitive nature of American society makes superiority claims particularly 
effective to an audience impressed with superiority. Especially concerning an important issue 
like health, having the “best” product is important and a factor that is sure to lure consumers. The 
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very clear, emphasized difference between Vytorin and other comparable drugs in the market 
also adds to Vytorin’s special and exclusive image. Consumers may also be drawn to Vyotrin’s 
emphasis of its combination of two cholesterol-lowering agents in one pill. While in the medical 
field quantity may not surpass quality in considerations of importance, to the lay consumer this 
claim may be particularly enticing. Without more information about the drug—which the 
advertisement neglects to provide—consumers are left to rely on their previous knowledge and 
value doctrines, including the prevalent conviction that two are better than one. 
 
E. Plavix (Appendix E) 
 Plavix’s advertising campaign between the years 1995 and 2010 has not been entirely 
consistent. Unlike its main market competitors, whose ads can be easily identified because they 
are part of a cohesive campaign, Plavix’s ads share certain similarities but are otherwise rather 
disparate. The main shared signifiers in the campaign, however, do stand out and isolate Plavix 
from other drug brands. Every single identified ad in the campaign includes both a physical 
image and a textual mention of the word “clot”. Unlike its competitors, who appear to generally 
focus on the risks of high cholesterol and define that condition as the drugs’ target, Plavix 
emphasizes the formation of clots in blood vessels. This distinction is important because it 
differentiates Plavix from its competitors and also introduces a condition fewer people—due to 
less advertising—are aware of, informed or concerned about. The emphasis on the word clot and 
its depiction in visual form creates a top-of-mind awareness for the consumer and primes the 
reader with the association of the word clot with a specific drug: Plavix. This recall could prove 
particularly important for a confused, uninformed consumer debating discussing a drug with a 
physician. 
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 The Plavix ads, while all centering on the threat of a clot, do so in different ways. One ad 
features a hospital emergency sign displayed backwards, indicating that the reader is inside the 
hospital, having already experienced a blood clot-related condition and claiming “Plavix could 
help keep you from coming back.” Another ad introduces Bob, a large, formidable-looking 
construction worker and states “he’s no match for something one millionth his size: a clot.” 
Another ad simply displays with the word “clot” in bold font filled with images of a clogged 
artery. A final advertisement shows a large image of a blood vessel superimposed with the 
headline “with miles and miles of arteries in your heart and brain, all it may take is the formation 
of one clot.” The contrast of the blown-up, large images and size of the text with the size of the 
threat addressed in the ad—a tiny, but deadly, clot—is very powerful. The visual representation 
of a clear versus a blocked artery is also effective in making the threat appear real and menacing. 
The overall tone of the ads is grave and intimidating, appearing as an almost overt attempt to 
scare the reader. 
 The drug company’s position in the ads is very clear—if the consumer is at risk, an active 
intervention is required to potentially save his/her life. Since clots are the number one problem 
and risk for those who have been previously hospitalized for cardiac conditions, Plavix offers to 
help protect against their formation. Plavix differentiates itself from other drugs in its category 
because unlike other heart medicines, it focuses specifically on clots and works to strengthen 
other cholesterol and blood pressure medications. This information is given in a narrative, rather 
than a didactic, style, describing the target condition, the advantages of Plavix, and the risk 
information associate with the drug. Although the advertisements make a rather blunt, aggressive 
statement at the outset, threatening the reader with a deadly clot and displaying grim images of 
hospital signs and sturdy men who do not stand a chance even against something as tiny as a 
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clot, after this initial hook the ads revert to an attempt to assuage the fear cued by the visuals in 
the ad and provide the reader with information on how to avoid the threats mentioned previously. 
The emphasis on the difference of Plavix from its competitors and its slightly different function 
than most cholesterol-lowering or blood pressure-controlling medications is effective in 
emphasizing its importance. The ad tries to be persuasive without being pushy, explaining that 
since Plavix is different from other medications it is not competing with them directly but will, 
instead, help protect heart health more fully. 
 The ad achieves credibility by capitalizing on its dissimilarity from other drugs in the 
market. The ads use authoritative warrants to try to convince the reader that Plavix is a necessary 
addition to a heart health protection regimen because it is different from other brands. Although 
the ads do not bombard the reader with too much text and information, it is enough to impart 
Plavix’s strengths and identify the target consumer for which it will be most effective. Without 
naming any of its competitors, Plavix is still able to make superiority and credibility claims about 
the efficacy and potency of the drug. Even though the validity of the major claims in the 
advertisements is not strongly corroborated, the ad seems authoritative and persuasive. 
 The Plavix campaign fits into the paradigmatic class of consumer intimidation. The 
emphasis on the fact that risk isn’t always associated with size, and that something as small as a 
microscopic blood clot could prove lethal in minutes, is a frightening prospect for readers. In 
addition, the ads’ suggestion that there is no surefire way to avoid clots further scares consumers 
and may make them more inclined to pursue a discussion about Plavix with their physicians just 
to decrease—though not entirely eliminate—the risk of something so ominous. Plavix’s offer to 
help avoid blood clots, then, is somewhat reassuring after the visual, textual, and emotional 
onslaught of panic and intimidation initially cued by the advertisements.  
 Wollstein 65 
 
 The order of priorities in the ad can be clearly seen in its syntax and the text’s 
arrangement throughout the layout. The visual element occupies the most space on the page, 
obviously meant to capture the reader’s attention and cue the fear that will motivate further 
examination of the advertisement. The description of the drug follows, emphasizing the 
difference of Plavix from other heart health medications. Lastly, a very brief mention of the 
drug’s side effects and important information is included at the bottom of the page in small, 
cramped text that does not invite perusal. The ads’ use of texts—such as the emergency sign or 
the “clot” written in clogged arteries—is an effective way of promoting the drug in one element. 
The association between the brand name and the word “clot” appears to be a priority for the 
brand and is effectively achieved by playing up this element, in different ways, throughout the 
campaign. 
 The Plavix ads draw on several cultural values to entice the consumer to pursue a 
prescription of the drug from a physician. The insistence that “Plavix can help keep you from 
coming back [from the hospital emergency room],” is a powerful stimulant of a feeling of trust in 
the drug and of the existence of a solution to the health threat. The use of text as part of the 
visual element of the advertisements makes use of today’s visual culture and tendency to focus 
more on visual elements than texts. By combining the two elements, the ads can promote 
Plavix’s message faster and, arguably, more effectively than an ad that only promotes the drug in 
the body of its text. Lastly, society’s general fear of death is capitalized upon in the ads’ 
persistent assertions of the vulnerability and mortality of man. The ads are effective not because 
they are necessarily appealing in their message, which is on the whole a grim one, but by their 
offer for a tool that could help avoid the undesirable outcomes of a blood clot. 
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3. Channel factors  
Channel factors, much like source factors, were kept constant in this analysis by 
purposely selecting advertising campaigns that were delivered in a similar fashion in comparable 
communication outlets and media. The choice of print media as the delivery venue for the 
campaigns studied holds several advantages for the type of analysis conducted here. Perhaps 
most importantly, print media’s low level of interactivity with its reader, contrasted with its high 
level of selectivity in targeting a particular demographic, demands advertisements that are both 
explicit and personalized. In print, limited space and readers’ attention compel advertisers to 
create advertisements that are clear in their purpose and presentation of the advertised product. In 
television, for instance, advertisers enjoy the luxury of being allotted a specific amount of time in 
which they are guaranteed the consumers’ undivided attention (should they continue to watch 
television on the same channel). This gives advertisers the freedom to create advertisements 
whose purpose may not be obvious until the end of the commercial, when an announcer can tie 
the elements of the commercial to the object it is promoting and a large, bold product name and 
logo can be flashed across the television screen, imploring consumers to seek out the advertised 
product. On the other hand, print media must be more straightforward or else risks losing not 
only audience members’ interest and attention but, fundamentally, full comprehension of the ad’s 
objective. As a result, print advertisements tend to be more compact (due to size and spread 
limitations), explicit, and to the point than their television counterparts. These features also make 
print ads a manageable and controllable medium that is conducive to this study. 
 
4. Receiver factors  
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The magazines from which advertisements were selected—Time Magazine, Reader’s 
Digest, People Magazine, and Newsweek—were chosen precisely to control for receiver 
variability. While it is clear that these magazines attract a wide demographic group, as evidenced 
by their large circulation sizes and national popularity, this attribute is, in fact, beneficial to this 
analysis. As discussed above, heart conditions afflict members of the population irrespective of 
gender, race, or nationality. The only generalization that can be made sweepingly in this category 
is based on the age of the average heart disease-susceptible individual, which tends to be 
relatively high (50+) in comparison to the average population. Accordingly, publications that 
appeal to a wide demographic were essential in order to capture the full scope of cardiovascular 
condition treatment drugs, which are targeted at a broad subset of the national population.  
Nevertheless, there are particular characteristics that can be attributed to readers of Time 
Magazine, Reader’s Digest, People Magazine, and Newsweek which correspond with 
pharmaceutical drug companies’ target audiences that are worth mentioning here. Studies have 
shown that although newspaper and newsmagazine readership is declining in favor of internet 
and television news consumption, the average age and affluence of readers is steadily 
increasing—to the delight of pharmaceutical drug advertisers. News magazines, like those 
selected for this study, attract news readers who generally tend to be older and have a 
significantly higher income than the U.S. adult population overall (Pew Research Center, 2004). 
Along the same vein, based on both the content of the magazines themselves and the socio-
economic attributes of the audiences attracted to these media channels, it can be assumed that the 
average news magazine-consuming population is relatively educated. These factors are important 
to pharmaceutical drug advertisers, as the kind of ads and appeals designed to sell the particular 
product must be well-tailored to its target demographic. In addition, this broadly-defined 
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demographic makes up precisely the target market pharmaceutical companies are seeking out: 
older, and thus more likely to be afflicted with some sort of (heart) health condition; wealthier, or 
with enough of a disposable income to consider brand-name, rather than generic, drugs for their 
health concerns; and more educated, and therefore possibly more inclined to read through the ad, 
understand its general claims, and be more motivated to seek out a prescription from their 
physician based on their self-diagnosis.  
 
5. Destination factors  
Finally, by selecting drugs from within the same pharmacological family that are targeted 
at the same broad demographic, the study attempted to control for the destination factors, or 
outcomes promoted by the communication. As with all direct-to-consumer advertisements, the 
objective of the advertisements is overt and clearly stated in every single ad: “Ask your doctor”. 
While this directive may, as studies have shown, imply more that the consumer should trouble 
their physicians for a prescription rather than obtain additional information about a particular 
drug from them, this objective is a hallmark of the direct-to-consumer trend. Since the premise of 
this form of advertising is that the consumer is being educated directly by the pharmaceutical 
companies, thus eliminating any risks of bias or pay-off of their doctors from the drug 
manufacturers, the destination objective is identical for all of the cases studied in this analysis.  
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V. Discussion  
 The individual examination of the advertising campaigns for the cardiac drugs Lipitor, 
Zocor, Pravachol, Vytorin, and Plavix (see results section) revealed a broad range of tactics 
employed by advertisers to entice consumers to seek a prescription for the drugs from a 
physician. Through a variety of techniques—including scare tactics, emotional appeals, and 
rationality appeals—advertisers have created campaigns that are persuasive and elicit compliance 
from consumers to purchase brand-name drugs. Now, a comparative and holistic evaluation is 
also warranted in order to draw some broad conclusions about these techniques and the concerns 
that arise with their use.  
 Especially notable in the comparison between the approaches of the various 
pharmaceutical companies to marketing their products is the type of appeal made to the 
consumer. Lipitor and Pravachol’s attempt to give the consumer as much factual—yet 
comprehensible—information contrasts sharply with Zocor’s personalized narrative style and 
emotional appeals, Vyotrin’s humorous approach, and Plavix’s scare tactics. Since these drugs 
are all targeted at the same demographic, it is illuminating to study their varying, but presumably 
comparably persuasive, methods of appeal. As it is known that all five drugs have enjoyed 
considerable market success, it seems that in addition to being apparently superior and effective 
drugs, the marketing campaigns designed for these pharmaceuticals have also been particularly 
persuasive to consumers, which has been reflected in their high sales numbers and market 
dominance. It is evident, then, that there is no single effective way of appealing to a rather wide, 
differentiated demographic that is defined more by its age range of 50+ than by any other 
demographic factor such as gender, race, or nationality. Attempting to keep all other factors as 
 Wollstein 70 
 
equal as possible, it appears that emotional, fear, and rationality cues are all effective in catching 
consumers’ attention and raising awareness of the drugs.  
 Perhaps that most evident, recurring theme emerging from the advertising campaign 
analyses is the sweeping move by pharmaceutical companies to empower the consumer and 
motivate him/her to seek a prescription for a particular drug. This shift of responsibility for the 
health of the individual from the traditionally-accountable physician directly to the patient 
him/herself is, as discussed previously, a characteristic feature of the direct-to-consumer strategy 
and constitutes a radical change in the established social roles of members of society. This 
change brings into question the power of physicians today, who as a result of this move are 
relegated to a role of prescription filling rather than of advising or initiating treatments. Although 
the physician is the ultimate gatekeeper for pharmaceutical distribution as controller of the 
prescription pad, as studies have shown doctors are feeling—and acting on—increased pressure 
from patients that has resulted in an influx of prescriptions for brand name drugs, even when 
such a prescription is not deemed entirely appropriate by the physician him/herself. In addition, 
while it is undoubtedly important that patients exercise some control over what medications they 
are being prescribed and are provided with sufficient information to make educated decisions 
about their health care routines, previous studies have also shown that the average American 
consumer does not possess adequate education or reading skills to make such informed 
decisions. This study’s findings, then, strongly support previous literature that has raised 
concerns about the appropriateness of addressing the consumer directly without the participation 
of an informed mediator intervening in the process. Feeling legitimate in their concern for their 
health and authorized to make decisions about pharmaceutical treatments, patients could prove 
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difficult to persuade or reason with when confronting a physician and demanding a prescription 
for a particular drug.  
 Another major problem raised by the literature and supported in this study is the lack of 
information made available to consumers in the advertisements themselves, rather than in the 
FDA-required additional information sections detailing the drugs’ common side effects, risks, 
and active ingredient information. First and foremost, the physical presence of this information is 
minimized by placing the information behind, rather than opposite, the actual advertisement in 
the magazines. That way, for more information a consumer would have to actively seek out the 
information by turning the page and reading its back side instead of having it readily displayed 
opposite the relevant ad. Not a single advertisement collected in the microfilm archives displayed 
the risk information next to the creative component of the advertisement. Further, the small, 
cramped text on the back page is made unappealing enough to discourage close reading even by 
a concerned or interested consumer.  
While this study did not analyze or evaluate the factual validity of the information and 
claims in the ads, it was exceedingly evident that even within the creative element of the 
advertisement, where the majority of the space was taken up by visuals or persuasive text rather 
than with factual information about the drugs, advertisers used various tactics to “hide” any 
actual information about the drug within the body of the text. As other studies have shown 
previously, the campaign analyses revealed that the ads tend to skim over important drug 
information and attempt to minimize the consumer’s exposure to facts that may deter the 
consumer from pursuing a prescription. As a result, the major claims made in the body of the text 
about things like the drug’s efficacy or potency went largely unsupported. The few statistics that 
were used in the ads seemed nonspecific and were not credited to any particular source or were 
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otherwise qualified. Any assurance of the drug’s safety or effectiveness was presented in the 
form of a statement claiming that the drug has been tested in clinical studies at a certain 
laboratory, though these claims were not expounded using any findings or backed by any 
relevant evidence. In all, the claims made in the advertisements were not well supported and did 
little to actually inform the consumer about the drugs’ qualities. 
Another major recurring theme in the advertising campaigns analyzed was the insistence 
on showing only the positive outcome of the threat of heart disease when confronted with the 
particular pharmaceutical the ad is trying to promote. Not only may the drug not work for every 
patient, but the list of side effects and possible risks just from taking the drug could result in very 
unpleasant circumstances. Nevertheless, the advertisements for Lipitor, Zocor, and Pravachol—
regardless of the types of cues each used to create a persuasive message—showed only smiling, 
happy-seeming models who, it can be inferred, took the advertised drug and are now free of the 
threat of heart attack, stroke, or blood clots. Vytorin and Plavix, on the other hand, avoided this 
problem entirely by choosing not to use models in their advertisements at all. While the emphasis 
on using highly relatable and happy models in the advertisements to entice consumers seems 
logical and obvious, it carries significant risk on the part of the consumer. Combined with 
previously-discussed elements such as the tendency to minimize the availability of information 
about the drug and the increased pressure on the patient to act as his/her own health advocate, the 
minimization of the appearance of risk and the assurance of safety and efficacy can be 
misleading and dangerous. The amount of rational, unbiased thinking a consumer who has been 
drawn in by a fear or emotional appeal like the threat of death or missing major life milestones 
can be expected to possess is minimal. Such a consumer, blinded by the smiling models that 
assure that the drug will solve all the patients’ problems, is severely compromised in a decision-
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making scenario. Without proper information to provide a “reality check” to counteract the 
scenarios depicted in the advertisements, it would be difficult for any individual to critically 
question the association the advertisements create between a frightening situation like heart 
disease and the promise of a tool to reduce its risks, as demonstrated by an enthusiastic and 
smiling model. 
The promise of a “miracle drug” to solve life’s various problems draws on yet another 
important theme worthy of discussion that is one of the major repercussions of the direct-to-
consumer advertising strategy. Previous literature has argued that one of the greatest risks posed 
by this promotional tactic is the medicalization of modern American society. According to this 
argument, Americans are being socialized to believe that every ill can be cured with the aid of a 
pharmaceutical. Instead of self-improvement in the form of lifestyle, diet, or exercise changes, 
pharmaceutical companies capitalize on the claim that consumers need not change their current 
way of life but can still solve their health problems with the simple addition of a particular drug 
to their daily regimen. While this is undoubtedly a tempting proposition, it is also painfully 
unrealistic. Even though patients really cannot fully control their cholesterol levels and risk of 
heart attack or blood clots, as many of the determining factors of these conditions are genetic, 
there are lifestyle changes that can be implemented to reduce cholesterol and lower the risk for 
some of these conditions. The suggestion by pharmaceutical companies that the risk of these 
conditions can be dissipated with a prescription for a particular advertised drug not only presents 
the options available to the consumer inaccurately, but also directly contributes to an increased 
consumption of expensive, brand-name drugs that have been raising health care costs. Beyond 
the discussion of the monetary and economic repercussions of the direct-to-consumer trend, 
which is not the focus of this analysis, the assertion that all health problems can be treated 
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pharmacologically is dangerous. Consumers who are not encouraged to make healthier life 
choices may be more likely to develop multiple health conditions that are caused by 
environmental (rather than genetic) factors in the future, which will require additional drug 
treatments. The lack of emphasis in these advertising campaigns on the risks associated with 
pharmacological treatments further play down the patient’s role in determining and controlling 
their own health. In stark contrast with the movement by the pharmaceutical industry to 
empower the individual as a consumer that can make his/her own choices and is prepared to 
spend money on pharmaceuticals to preserve his/her health, the role of the individual as the 
healthy, fit maintainer of general health and maker of sound choices that promote well-being is 
sorely diminished. 
Textual analysis can be a useful tool for evaluating some of the prevalent values of the 
society for which the analyzed text is constructed. This form of analysis reveals the types of 
values present in culture and advertisers’ manipulation of these values to create a desired effect. 
The analysis conducted here uncovered several important values which, used correctly by 
advertisers, have elicited a consumer response in the form of sales and significant market 
success. The expert use of visuals, the ubiquitous presence of an assuring figure or statistic, and 
the emphasis on quick, easy, and powerful solutions stem directly from modern culture’s 
demands. Today’s visual culture practically demands advertisements that are visually appealing 
and enticing rather than informative. Advertisers would be much less inclined to create ads that 
are crowded with text (and include important information), because consumers have shown a 
lack of time, interest, and draw to such communications. The general trust in numbers and 
statistics has also prompted advertisers to display at least one such statement prominently in all 
ads analyzed. It seems that even when the claims in the advertisements are largely unqualified 
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and unsubstantiated, they are still effective in establishing credibility for the brand and trust in 
the drug. This inclination to trust statistics without proper evidence or confirmation could be 
dangerous, especially in the drug arena where most consumers are simply not well enough 
informed or properly educated to make reasoned decisions.  
Today’s fast-paced, non-stop world calls for fast and easy products. This need is also 
reflected in the advertising strategy for these goods, which is designed more to catch the 
consumer’s attention and draw it away from competing stimuli rather than to inform. In the case 
of pharmaceuticals, this tendency is particularly worrisome. In a field where it is essential to be 
well informed, and the average consumer is not, and where the role of the physician is showing 
worrying signs of diminishing in influence, the complex nature of the product cannot be 
communicated in an advertisement that is designed to be eye catching above all else. Advertisers, 
it can be argued, are simply responding to social trends. But, it is important to note, they are also 
perpetuating them. This is a unique power that must be carefully weighed in deliberations for 
future policies to regulate this form of advertising.  
 
Recently, new developments in the pharmaceutical arena threaten to change the current 
status-quo of brand-name drug domination of the pharmaceutical market. This market remains a 
lucrative, “booming opportunity” that companies vie to dominate (Sanders, 2001, p. 4);  
moreover, it shows signs of expanding even further as developments such as the National 
Institutes of Health revising and lowering the cholesterol number that indicates a person is at risk 
for cardiac conditions associated with high cholesterol take place. This move alone drastically 
increases the number of Americans are now considered eligible for cholesterol-lowering 
medications from 12.5 million to 36 million (Sanders, 2001, p. 4). As major-name, market-
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dominating pharmaceuticals such as Lipitor and Plavix lose patent protection, generic-brand 
drugs will quickly flood the market with cheaper versions of the drugs and will jeopardize the 
monopoly currently enjoyed by the market leaders (Iskowitz, 2011, p. 38). This pressure for 
continued success is pushing pharmaceutical companies to invest resources in developing new 
approaches to treating conditions, discovering new active ingredients, and maximizing the 
effectiveness and potency of their drugs. Surely, these changes will be reflected in the 
companies’ future advertising campaigns as they struggle to compete with their cheaper, generic 
counterparts. While it remains unclear if this fear of overtake by generics will be realized, the 
effect of these changes on product and advertising strategy will be interesting to observe and 
would serve as an important object for further study.  
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